[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 376
1. Green RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB: Bevacizumab for recurrent ependymoma. Neurology; 2009 Nov 17;73(20):1677-80
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab for recurrent ependymoma.
  • BACKGROUND: Ependymoma is a rare type of glioma, representing 5% of all CNS malignancies.
  • At recurrence, ependymoma is notoriously refractory to therapy and the prognosis is poor.
  • METHODS: In this Institutional Review Board-approved study, we retrospectively analyzed the records of 8 adult patients treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens.

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):211-6 [15614581.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):159-67 [19019565.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):143-8 [15912507.001]
  • (PMID = 19917990.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / UO1 CA-105663-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2788805
  •  go-up   go-down


2. Barton VN, Donson AM, Kleinschmidt-DeMasters BK, Birks DK, Handler MH, Foreman NK: Unique molecular characteristics of pediatric myxopapillary ependymoma. Brain Pathol; 2010 May;20(3):560-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unique molecular characteristics of pediatric myxopapillary ependymoma.
  • Myxopapillary ependymoma (MEPN) generally can be cured by gross total surgical resection and usually manifest a favorable prognosis.
  • Clinical trial design requires a better understanding of tumor biology.
  • Unique molecular features of MEPN were investigated by using microarray technology to compare the gene expression of five pediatric MEPN to 24 pediatric intracranial ependymoma (EPN).
  • The upregulation of three genes of interest, homeobox B13 (HOXB13), neurofilament, light polypeptide (NEFL) and PDGFR alpha, was further studied by immunohistochemistry in a larger cohort that included adult MEPN and EPN specimens.
  • Protein expression in MEPN was compared to subependymoma, spinal EPN, intracranial EPN and normal fetal and adult ependyma.
  • [MeSH-major] Ependymoma / genetics. Ependymoma / metabolism. Nerve Tissue Proteins / genetics. Nerve Tissue Proteins / metabolism. Spinal Cord Neoplasms / genetics. Spinal Cord Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Cohort Studies. Female. Humans. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Myxopapillary ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurosurg. 2000 Jan;32(1):30-6 [10765136.001]
  • [Cites] Cancer. 2009 Sep 1;115(17):3955-68 [19536879.001]
  • [Cites] Med Pediatr Oncol. 2000 Oct;35(4):443-5 [11025481.001]
  • [Cites] Behav Brain Res. 2001 Nov 1;125(1-2):279-84 [11682119.001]
  • [Cites] Prostate. 2002 Feb 15;50(3):162-9 [11813208.001]
  • [Cites] Leukemia. 2002 Feb;16(2):186-95 [11840284.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Exp Cell Res. 2004 Feb 1;293(1):144-53 [14729064.001]
  • [Cites] Acta Neurochir (Wien). 2004 Nov;146(11):1255-8 [15365794.001]
  • [Cites] J Surg Oncol. 1983 Jan;22(1):33-6 [6823114.001]
  • [Cites] Cell. 1984 Oct;38(3):667-73 [6091895.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):31-6 [2909684.001]
  • [Cites] Nucleic Acids Res. 1989 Dec 25;17(24):10385-402 [2574852.001]
  • [Cites] Childs Nerv Syst. 1991 Aug;7(4):177-82 [1933913.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):237-44 [7678830.001]
  • [Cites] Childs Nerv Syst. 1993 Feb;9(1):3-6 [8481942.001]
  • [Cites] Acta Neurochir (Wien). 1993;124(2-4):99-103 [8304078.001]
  • [Cites] Pediatr Neurosurg. 1998 May;28(5):273-8 [9732262.001]
  • [Cites] Pediatr Neurosurg. 1998 Jun;28(6):314-9 [9782208.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3045-50 [9865919.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):953-8 [9869215.001]
  • [Cites] Leukemia. 1999 May;13(5):687-98 [10374871.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):627-32 [10433955.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):25-8 [15803371.001]
  • [Cites] J Neurosurg. 2005 Jan;102(1 Suppl):59-64 [16206735.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5223-33 [17114655.001]
  • [Cites] Acta Neuropathol. 2007 Mar;113(3):325-37 [17265049.001]
  • [Cites] J Neurooncol. 2007 May;83(1):85-9 [17206474.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5806-13 [17575148.001]
  • [Cites] Dev Dyn. 2007 Sep;236(9):2454-63 [17685480.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Aug;66(8):740-9 [17882018.001]
  • [Cites] Cancer Invest. 2008 Dec;26(10):990-8 [19093257.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):470-5 [19156136.001]
  • [Cites] Expert Opin Ther Targets. 2009 Apr;13(4):443-54 [19335066.001]
  • [Cites] Neurosurg Rev. 2009 Jul;32(3):321-34; discussion 334 [19221818.001]
  • [Cites] Nature. 2000 Jun 22;405(6789):974-8 [10879542.001]
  • (PMID = 19793339.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins
  • [Other-IDs] NLM/ PMC2871180
  •  go-up   go-down


3. Chamberlain MC, Johnston SK: Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma. Cancer; 2009 Oct 15;115(20):4775-82
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma.
  • BACKGROUND: To the authors' knowledge, there currently is no standard therapy for platinum-resistant ependymoma; hence, a need exists for new therapies.
  • In the current study, a retrospective evaluation of temozolomide (TMZ) in adults with recurrent, supratentorial, platinum-refractory, World Health Organization grade 2 ependymoma was performed, with an objective of determining 6-month progression-free survival (PFS).
  • METHODS: A total of 25 patients, ages 28 to 63 years, with recurrent ependymoma were treated.
  • Time to tumor progression ranged from 1 to 7 months (median, 2 months).
  • CONCLUSIONS: TMZ in this dose schedule demonstrated little efficacy in a cohort of adults with recurrent, intracranial, platinum-refractory ependymoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Ependymoma / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Ferrous Compounds. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retreatment

  • Genetic Alliance. consumer health - Ependymoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19569246.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Ferrous Compounds; 33269-57-7 / EX 10-478; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Rousseau E, Palm T, Scaravilli F, Ruchoux MM, Figarella-Branger D, Salmon I, Ellison D, Lacroix C, Chapon F, Mikol J, Vikkula M, Godfraind C: Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma. Mol Cancer; 2007;6:47
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma.
  • Ependymal tumors constitute a clinicopathologically heterogeneous group of brain tumors.
  • We define a newly recognized subset of ependymal tumors, the trisomy 19 ependymoma.
  • When containing clear cells they are called clear cell ependymoma.
  • These altered chromosomal regions are indicative of genes and pathways involved in trisomy 19 ependymoma tumorigenesis.
  • [MeSH-major] Brain Neoplasms / pathology. Chromosomes, Human, Pair 19 / genetics. Ependymoma / pathology. Trisomy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Chromosome Deletion. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 9 / genetics. Female. Genome, Human. Humans. Infant. Male. Microsatellite Repeats / genetics. Middle Aged. Nucleic Acid Hybridization / methods. Polymorphism, Single Nucleotide. Tissue Array Analysis / methods. Tissue Fixation / methods

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1994 Oct 7;79(1):119-30 [7923370.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):141-52 [12790776.001]
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):820-6 [9236838.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11268-73 [9326598.001]
  • [Cites] Surg Neurol. 1999 Mar;51(3):281-7; discussion 287-8 [10086492.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):361-8 [15781323.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3193-9 [15833850.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3542-7 [15867346.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Oct;29(5):462-71 [14507338.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):385-8 [12898159.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2232-44 [14601094.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Dec;29(6):574-83 [14636164.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):9-14 [14631364.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):24-30 [15108012.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9527-41 [15485920.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;415(5):467-72 [2477945.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6071-9 [16024607.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(18):7953-65 [16135788.001]
  • [Cites] Cancer Biol Ther. 2005 Nov;4(11):1216-21 [16357509.001]
  • [Cites] Genomics. 2006 Feb;87(2):298-306 [16271290.001]
  • [Cites] J Biol Chem. 2006 Mar 10;281(10):6664-72 [16317011.001]
  • [Cites] Calcif Tissue Int. 2006 Apr;78(4):233-40 [16604287.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Apr 1;166(1):74-81 [16616114.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):268-76 [16645215.001]
  • [Cites] J Biol Chem. 2006 May 26;281(21):14711-8 [16595680.001]
  • [Cites] Scand J Immunol. 2006 Jun;63(6):391-400 [16764692.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):958-62 [16648869.001]
  • [Cites] Lab Invest. 2006 Sep;86(9):968-78 [16751780.001]
  • [Cites] Acta Neuropathol. 2007 Mar;113(3):325-37 [17265049.001]
  • [Cites] J Mol Med (Berl). 2007 Mar;85(3):293-304 [17143621.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):73-84 [10668897.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):824-6 [10835513.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):1137-43 [11238062.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46460-8 [11585837.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1109-19 [11106750.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):929-39 [11953826.001]
  • [Cites] Mod Pathol. 2002 May;15(5):526-31 [12011257.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:a1-9 [12456321.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2133-41 [12466129.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • (PMID = 17626628.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1950527
  •  go-up   go-down


5. Adamson DC, Cummings TJ, Friedman AH: Myxopapillary Ependymoma and Fatty Filum in an Adult with Tethered Cord Syndrome: A Shared Embryological Lesion? Case Report. Neurosurgery; 2005 Aug 01;57(2):E373

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxopapillary Ependymoma and Fatty Filum in an Adult with Tethered Cord Syndrome: A Shared Embryological Lesion? Case Report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184710.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Andrade FG, de Aguiar PH, Matushita H, Taricco MA, Oba-Shinjo SM, Marie SK, Teixeira MJ: Intracranial and spinal ependymoma: series at Faculdade de Medicina, Universidade de São Paulo. Arq Neuropsiquiatr; 2009 Sep;67(3A):626-32
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial and spinal ependymoma: series at Faculdade de Medicina, Universidade de São Paulo.
  • METHOD: Data of clinical presentation, tumor location, duration of symptoms, degree of resection and complementary treatment of 34 patients with intracranial ependymoma and 31 with intramedullary ependymoma who underwent surgery in the last ten years were collected and correlated with the recurrence time and overall survival.
  • RESULTS: There was statistically significant correlation between the degree of resection and intracranial tumor location, although it is not a hallmark of recurrence.
  • Data analyses of intramedullary ependymoma did not show correlation with overall survival and likelihood of recurrence.
  • CONCLUSION: The location of the intracranial tumor is connected with the degree of resection; however it is not a predictive factor to overall survival.
  • [MeSH-major] Brain Neoplasms / surgery. Ependymoma / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Disease-Free Survival. Female. Hospitals, University. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722039.001).
  • [ISSN] 1678-4227
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


7. Morris EB, Li C, Khan RB, Sanford RA, Boop F, Pinlac R, Xiong X, Merchant TE: Evolution of neurological impairment in pediatric infratentorial ependymoma patients. J Neurooncol; 2009 Sep;94(3):391-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of neurological impairment in pediatric infratentorial ependymoma patients.
  • BACKGROUND: Infratentorial ependymoma is a common central nervous system tumor of childhood and in patients >1 year of age is treated with maximally feasible surgical resection and radiotherapy.
  • Because of this tumor typically arises within the 4th ventricle and can invade the brainstem, patients are at risk for significant neurological impairment.
  • PURPOSE: To characterize the incidence, evolution, and persistence of neurologic impairment in children with infratentorial ependymoma following maximal safe surgery and conformal or intensity-modulated radiation therapy (CRT/IMRT).
  • PATIENTS AND METHODS: After surgical resection, 96 children with non-metastatic infratentorial ependymoma were enrolled on a phase II study of image-guided radiation therapy and were prospectively followed with interval comprehensive neurological examinations.

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):892-9 [18395355.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Mar;20(2):89-101 [12554520.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1347-51 [12663725.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] Cancer. 1976 Feb;37(2 Suppl):1149-51 [1253128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Jun;7(6):727-36 [7287533.001]
  • [Cites] Med Pediatr Oncol. 1990;18(4):304-10 [2355890.001]
  • [Cites] Arch Dis Child. 1990 Dec;65(12):1356-63 [2270944.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):781-7 [7960979.001]
  • [Cites] J Child Neurol. 1995 May;10(3):209-12 [7642890.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31 [9589080.001]
  • [Cites] J Neurooncol. 1999 Jan;41(1):47-53 [10222422.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7143-51 [16192598.001]
  • [Cites] Contemp Clin Trials. 2006 Jun;27(3):269-73 [16388989.001]
  • [Cites] J Ky Med Assoc. 1999 Oct;97(10):465-71 [10544553.001]
  • (PMID = 19330288.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-30; United States / NCI NIH HHS / CA / P30 CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS105709; NLM/ PMC2731005
  •  go-up   go-down


8. Wright KD, Gajjar A: New chemotherapy strategies and biological agents in the treatment of childhood ependymoma. Childs Nerv Syst; 2009 Oct;25(10):1275-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.
  • INTRODUCTION: With the limited role of current treatment regimens and potential associated side effects of radiation in young children with ependymoma, considerable effort is being focused on new chemotherapeutic strategies and biologic agents.
  • DISCUSSION AND CONCLUSION: Identification of those molecular changes underlying the development of ependymoma may, in time, lead to the development of not only novel therapeutic agents, but also specific patient-tailored therapies directed against known cell-signaling pathways.

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1998 Apr;88(4):695-703 [9525716.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Mar-Apr;20(2):125-30 [9544162.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3932-41 [9731505.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 May-Jun;21(3):203-11 [10363853.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Sep;27(9):486-90 [16189442.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):452-64 [16212810.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):432-41 [17559078.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):231-5 [17610266.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):418-24 [18245671.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):209-16 [18386816.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Oct;8(10):1545-57 [18925847.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4921-7 [18794549.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):701-7 [19147777.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4143-55 [10590059.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):505-15 [10688871.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1045-7 [10772648.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(10):1248-57 [10882863.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1288-96 [11230470.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Nov;27(11):573-81 [16282886.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):1-3 [16330665.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] Annu Rev Med. 2006;57:83-97 [16409138.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1522-8 [16575002.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2070-9 [16609018.001]
  • [Cites] Science. 2006 May 26;312(5777):1171-5 [16728631.001]
  • [Cites] J Chemother. 2006 Apr;18(2):188-91 [16736888.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5190-8 [16951238.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14):2335-42 [16899365.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):876-85 [17036041.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5223-33 [17114655.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Nov;28(11):720-8 [17114958.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1511-5 [17332296.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):34-40 [16874765.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):705-12 [11531256.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):45S-51S [11560971.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):73-80 [11863115.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):87-94 [11949831.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):727-39 [12360276.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3054-64 [12374672.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2133-41 [12466129.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):140-8 [12517790.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):12-20 [12644980.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1643-8 [14534880.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Nov;52(5):377-82 [12879280.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):941-9 [14967454.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1212-8 [14977817.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] Cancer Treat Rep. 1982 Dec;66(12):2013-20 [6890409.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1497-501 [4040799.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):62-6 [2826716.001]
  • [Cites] J Neurosurg. 1990 Mar;72(3):408-17 [2303876.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2465-9 [2249186.001]
  • [Cites] Pediatr Neurosurg. 1990-1991;16(2):57-65 [2132926.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):249-56 [1732426.001]
  • [Cites] J Neurooncol. 1992 Jul;13(3):283-90 [1517804.001]
  • [Cites] Med Pediatr Oncol. 1993;21(1):49-53 [8381203.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1607-15 [8040673.001]
  • [Cites] Neurosurgery. 1995 Oct;37(4):655-66; discussion 666-7 [8559293.001]
  • [Cites] Med Pediatr Oncol. 1996 Jul;27(1):8-14 [8614396.001]
  • [Cites] Pediatr Neurosurg. 1996;24(3):119-25 [8870014.001]
  • [Cites] J Neurooncol. 1997 May;32(3):243-52 [9049886.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):856-60; discussion 860 [9092863.001]
  • [Cites] Med Pediatr Oncol. 1997 Jul;29(1):28-32 [9142202.001]
  • [Cites] Med Pediatr Oncol. 1997 Aug;29(2):79-85 [9180907.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):341-7 [9217048.001]
  • [Cites] Eur J Cancer. 1997 Apr;33(4):609-15 [9274443.001]
  • (PMID = 19212772.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-30; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Quinazolines; 2S9ZZM9Q9V / Bevacizumab; DA87705X9K / Erlotinib Hydrochloride; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS85887; NLM/ PMC2738756
  •  go-up   go-down


9. Higgins GS, Smith C, Summers DM, Statham PX, Erridge SC: Myxopapillary ependymoma with intracranial metastases. Br J Neurosurg; 2005 Aug;19(4):356-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxopapillary ependymoma with intracranial metastases.
  • We report spontaneous seeding within the subarachnoid space from a myxopapillary ependymoma that progressed despite surgery and radiotherapy treatment.
  • [MeSH-major] Brain Neoplasms / secondary. Ependymoma / secondary. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Lumbar Vertebrae. Magnetic Resonance Imaging. Subarachnoid Space. Thoracic Vertebrae

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Myxopapillary ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Neurosurg. 2006 Apr;20(2):114 [16753632.001]
  • (PMID = 16455546.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Wang Z, Huang G, Yan P, Liang R, Wang J, Yan Q, Zhang J, Cheng H, Hu P, Ma MJ: Ectopic cervical anaplastic ependymoma. Pathol Int; 2005 Dec;55(12):781-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic cervical anaplastic ependymoma.
  • Ependymomas generally arise in the central nervous system (CNS), although rare primary extraneural ependymomas have been observed.
  • Reported herein for the first time is the case of a patient with primary ectopic cervical anaplastic ependymoma.
  • The tumor was found in the right neck root region of a 35-year-old man.
  • No additional tumor was found in the CNS or in other parts of the body.
  • Microscopically, the tumor consisted of round to oval cells with fine chromatin, distinct nucleoli, moderate nuclear atypia and numerous mitoses (>25/10 high-power fields) in a densely cellular growth pattern with characteristic fibrillary cytoplasm and formation of perivascular pseudorosettes.
  • By immunohistochemistry, the tumor cells were positive for glial fibrillary acidic protein, epithelial membrane antigen (EMA), vimentin and S-100 protein.
  • EMA staining showed a membranous as well as a paranuclear pattern of immunoreactivity.
  • Electron microscopic studies revealed that tumor cells form micro rosettes, into which microvilli and cilia projected.
  • The diagnosis was World Health Organization grade III anaplastic ependymoma.
  • There is no evidence of local tumor recurrence or distant metastasis after 30 months follow up.
  • [MeSH-major] Ependymoma / pathology. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Adult. Glial Fibrillary Acidic Protein / analysis. Humans. Male. Mucin-1 / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Anaplastic Ependymoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287493.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Vimentin
  •  go-up   go-down


11. Ulrich CT, Beck J, Seifert V, Marquardt G: Ependymoma of conus medullaris presenting as subarachnoid haemorrhage. Acta Neurochir (Wien); 2008 Feb;150(2):185-8
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymoma of conus medullaris presenting as subarachnoid haemorrhage.
  • Subarachnoid haemorrhage (SAH) due to spinal ependymoma is very rare.
  • Lumbar puncture confirmed SAH but cerebral angiography was negative, and further diagnostic work-up revealed an ependymoma of the conus medullaris as the source of the haemorrhage.
  • Only 17 patients with spontaneous SAH due to a spinal ependymoma have been reported since 1958.
  • [MeSH-major] Ependymoma / complications. Ependymoma / diagnosis. Spinal Cord Neoplasms / complications. Spinal Cord Neoplasms / diagnosis. Subarachnoid Hemorrhage / etiology
  • [MeSH-minor] Adult. Humans. Lumbar Vertebrae. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058061.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 17
  •  go-up   go-down


12. Kawabata Y, Takahashi JA, Arakawa Y, Hashimoto N: Long-term outcome in patients harboring intracranial ependymoma. J Neurosurg; 2005 Jul;103(1):31-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome in patients harboring intracranial ependymoma.
  • OBJECT: The prognostic significance of tumor grade and resection and the efficacy of prophylactic radiation remain controversial in the management of intracranial ependymoma.
  • The outcomes in patients with intracranial ependymoma treated at the Kyoto University Hospital were reviewed retrospectively, and prognostic significance was analyzed.
  • Eighteen cases involved a Grade II lesion according to the World Health Organization classification of ependymoma and 11 involved a Grade III lesion.
  • Overall survival and progression-free survival rates were significantly higher in patients with Grade II ependymoma (p = 0.006 and 0.004, respectively) and in patients who had undergone gross-total resection of the tumor (p = 0.002 and 0.04, respectively).
  • In nine patients the ependymoma recurred only at the original tumor site.
  • All relapses of the Grade II ependymoma initially occurred at the primary tumor site.
  • Histological grade and extent of resection were significantly associated with tumor dissemination (p = 0.0034 and 0.0011, respectively).
  • CONCLUSIONS: Tumor grade and resection are the two important prognostic factors with respect to patient survival, tumor recurrence, and tumor dissemination.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / therapy. Ependymoma / mortality. Ependymoma / therapy. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2006 Sep;105(3):503; author reply 503-4 [16961153.001]
  • [CommentIn] J Neurosurg. 2005 Jul;103(1):4; discussion 4-5 [16121965.001]
  • (PMID = 16121970.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Matsuyama A, Hisaoka M, Yamamoto I, Toyoshima S, Hashimoto H: Extraspinal ependymoma of the broad ligament. Pathol Int; 2010 Mar;60(3):241-4
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraspinal ependymoma of the broad ligament.
  • Extraspinal ependymoma is a rare tumor, occurring most commonly in the sacrococcygeal region, and only a small number of cases have been reported to arise in the uterine ligament.
  • Herein is reported a case of extraspinal ependymoma arising in the broad ligament of a 27-year-old woman.
  • On cut section the tumor was found to be solid, and demonstrated hemorrhaging, necrosis, myxoid foci, and central cystic spaces.
  • Microscopically the tumor was composed of a proliferation of short spindle or polygonal cells arranged in short fascicles or in a solid sheet-like fashion with occasional perivascular pseudorosettes, together with myxoid areas and variable histological architectures exhibiting cribriform, pseudopapillary, and variable-sized cystic patterns.
  • On immunohistochemistry most tumor cells were positively reactive to glial fibrillary acidic protein (GFAP), CD99, estrogen receptor, and progesterone receptor.
  • Extraspinal ependymoma should be considered as a differential diagnosis when examining unusual intrapelvic tumors, especially in young female patients.
  • [MeSH-major] Broad Ligament / pathology. Ependymoma / pathology. Genital Neoplasms, Female / pathology
  • [MeSH-minor] Adult. Cell Proliferation. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Immunohistochemistry. Ovariectomy. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403052.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


14. Tay A, Scheithauer BW, Cameron JD, Myhre MJ, Boerner MJ: Retinal ependymoma: an immunohistologic and ultrastructural study. Hum Pathol; 2009 Apr;40(4):578-83
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal ependymoma: an immunohistologic and ultrastructural study.
  • Ependymoma is exquisitely rare.
  • Herein, we report the clinicopathologic features of the second case of retinal ependymoma.
  • The tumor was sporadic in occurrence and unilateral, low grade, and of cellular type.
  • The literature regarding retinal glial neoplasia including ependymoma as well as the so-called massive retinal gliosis is discussed.
  • [MeSH-major] Ependymoma / ultrastructure. Retinal Neoplasms / ultrastructure
  • [MeSH-minor] Adult. Eye Evisceration. Female. Humans. Immunohistochemistry. Microscopy, Electron, Transmission. Retinal Detachment / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18835620.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Gupta R, Rishi A, Suri V, Sharma MC, Gupta A, Garg A, Sarkar C: Sacral myxopapillary ependymoma with extensive osteolysis. J Neurooncol; 2008 Feb;86(3):349-52
Genetic Alliance. consumer health - Myxopapillary ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sacral myxopapillary ependymoma with extensive osteolysis.
  • Myxopapillary ependymoma rarely presents as a primary intra-sacral lesion and extensive bony destruction is unusual.
  • We report the case of a 42-year-old man with a primary intra-sacral myxopapillary ependymoma causing extensive osteolysis.
  • [MeSH-major] Ependymoma / complications. Osteolysis / complications. Sacrum / pathology. Spinal Neoplasms / complications
  • [MeSH-minor] Adult. Glial Fibrillary Acidic Protein / metabolism. Humans. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. Nuclear Proteins / metabolism. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952371.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / S100 Proteins
  •  go-up   go-down


16. Sarikaya S, Acikgöz B, Tekkök IH, Güngen YY: Conus ependymoma with holocord syringohydromyelia and syringobulbia. J Clin Neurosci; 2007 Sep;14(9):901-4
MedlinePlus Health Information. consumer health - Syringomyelia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conus ependymoma with holocord syringohydromyelia and syringobulbia.
  • We report a 24-year-old woman with an intramedullary conus ependymoma associated with holocord syringohydromyelia and syringobulbia.
  • The tumor was removed and surgery for decompression of the syringohydromyelia was not considered at the first operation.
  • The cause of syringohydromyelia accompanying intradural spinal cord tumors appears to be either direct blockade of the central canal or secondary interruption of the central canal flow by compression of the perimedullary cerebrospinal fluid flow.
  • [MeSH-major] Brain Stem Neoplasms / complications. Ependymoma / complications. Spinal Neoplasms / complications. Syringomyelia / complications
  • [MeSH-minor] Adult. Decompression, Surgical / methods. Female. Humans. Magnetic Resonance Imaging / methods

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Syringobulbia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660060.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


17. Wright KD, Rand V, Leary SE, Mack S, Coyle B, Gillespie Y, Allen J, Taylor MD, Grundy R, Gilbertson RJ: A comprehensive view of the structure and expression of the ependymoma genome at presentation and relapse. J Clin Oncol; 2009 May 20;27(15_suppl):2073

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comprehensive view of the structure and expression of the ependymoma genome at presentation and relapse.
  • : 2073 Background: Although pediatric and adult ependymomas are associated with significant mortality and morbidity, little is known about the biology of these tumors.
  • To identify underlying genetic alterations and cellular pathways that drive this disease, we conducted a genomic study of 200 adult and pediatric ependymomas.
  • Integrated genetic and expression mapping revealed key candidate tumor suppressor (TSG) and onco- genes, likely drivers of these large alterations.
  • Our cohort also included five sample sets consisting of primary tumor and at least two corresponding relapses.
  • Genomic analysis of these tumors identified large chromosomal alterations as well as focal gains and losses associated with disease relapse.
  • CONCLUSIONS: We present a highly comprehensive view of the ependymoma genome, including 80 previously unrecognized candidate TSG and oncogenes that may afford diagnostic and therapeutic targets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964381.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Miyazawa T, Hirose T, Nakanishi K, Uozumi Y, Tsuzuki N, Shima K: Supratentorial ectopic cortical ependymoma occurring with intratumoral hemorrhage. Brain Tumor Pathol; 2007;24(1):35-40
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial ectopic cortical ependymoma occurring with intratumoral hemorrhage.
  • We report here a rare case of supratentorial ectopic cortical ependymoma.
  • This tumor was localized in the left angular gyrus, occurred with intratumoral hemorrhage, was attached to the dura mater, exhibited no continuity with the ventricular system, showed distinctive pathological features (perivascular pseudo-rosette formations and firework-like giant rosette formations), and finally transformed to a glioblastoma-like high-grade lesion.
  • A cortical ependymoma should be considered in the differential diagnosis of supratentorial cortical tumors with intraparenchymal hemorrhage and high vascularity, even if not in contact with the ventricular system.
  • Although malignant transformation is unusual in cortical ependymoma, close observation and adjunctive radiotherapy are strongly recommended after the excision.
  • [MeSH-major] Ependymoma / pathology. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adult. Hemorrhage / etiology. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095143.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Massimino M, Buttarelli FR, Antonelli M, Gandola L, Modena P, Giangaspero F: Intracranial ependymoma: factors affecting outcome. Future Oncol; 2009 Mar;5(2):207-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial ependymoma: factors affecting outcome.
  • The management of intracranial ependymoma is still not optimal.
  • The 5-year progression-free survival for children with ependymoma ranges between 30 and 50% with a worse prognosis for patients with residual disease after surgery.
  • For high-risk patients, with residual tumor, an interesting, although experimental, approach could be chemotherapy followed by secondary surgery and postoperative conformal irradiation.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology
  • [MeSH-minor] Adult. Biomarkers / analysis. Child. Humans. Prognosis

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19284379.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 68
  •  go-up   go-down


20. Lord H, Ironside J, Summers D, Gregor A, Erridge S, Myles L: Fourth ventricle ependymoma in father and son. Br J Neurosurg; 2008 Jun;22(3):423-5
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fourth ventricle ependymoma in father and son.
  • A father and son presented ten years apart with a fourth ventricle ependymoma.
  • The history, imaging and pathology are presented and the aetiology of familial ependymoma discussed.
  • [MeSH-major] Cerebral Ventricle Neoplasms / genetics. Ependymoma / genetics. Fourth Ventricle
  • [MeSH-minor] Adult. Humans. Male. Middle Aged. Pedigree. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952721.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Roncaroli F, Consales A, Fioravanti A, Cenacchi G: Supratentorial cortical ependymoma: report of three cases. Neurosurgery; 2005 Jul;57(1):E192; discussion E192
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial cortical ependymoma: report of three cases.
  • Here, we report three patients with supratentorial intracortical ependymoma.
  • [MeSH-major] Brain Neoplasms / surgery. Ependymoma / surgery. Neurosurgery / methods. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Microscopy, Electron, Transmission / methods. Middle Aged. Radiotherapy / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15987557.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kano H, Niranjan A, Kondziolka D, Flickinger JC, Lunsford LD: Outcome predictors for intracranial ependymoma radiosurgery. Neurosurgery; 2009 Feb;64(2):279-87; discussion 287-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome predictors for intracranial ependymoma radiosurgery.
  • OBJECTIVE: To develop outcome predictors after stereotactic radiosurgery (SRS) in patients with intracranial ependymomas who had received previous fractionated radiation therapy, we compared tumor control, survival, and complications with tumor grade, volume, age of patients, and imaging characteristics.
  • METHODS: We retrospectively reviewed records of 39 consecutive ependymoma patients who underwent SRS for 56 tumors.
  • Lower histological tumor grade was not significantly associated with better progression-free survival (P = 0.725).
  • Factors associated with an improved progression-free survival included smaller tumor volume and homogeneous tumor contrast enhancement in low-grade ependymomas.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / surgery. Ependymoma / epidemiology. Ependymoma / surgery. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Outcome Assessment (Health Care) / methods. Radiosurgery / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Incidence. Male. Middle Aged. Pennsylvania / epidemiology. Retrospective Studies. Risk Assessment / methods. Risk Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190457.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Hamilton DW, Lusher ME, Lindsey JC, Ellison DW, Clifford SC: Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Lett; 2005 Sep 8;227(1):75-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma.
  • To investigate the role of aberrant epigenetic events in ependymoma and identify critical genes in its pathogenesis, the methylation status of nine tumour suppressor genes (TSGs: p14(ARF), p15(INK4B), p16(INK4A), CASP8, MGMT, TIMP3, TP73, RB1 and RASSF1A) was assessed.
  • Extensive hypermethylation across the RASSF1A CpG island was detected frequently in ependymomas of all clinical and pathological disease subtypes (86% of cases, n=35), but not in non-neoplastic brain tissues (n=6).
  • RASSF1A hypermethylation represents the most common gene-specific defect identified in ependymoma highlighting the importance of its further investigation in this disease.
  • [MeSH-major] Ependymoma / genetics. Genes, Tumor Suppressor. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. CpG Islands. DNA Methylation. Epigenesis, Genetic. Female. Humans. Male

  • Genetic Alliance. consumer health - Ependymoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051033.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


24. Alkhani A, Blooshi M, Hassounah M: Outcome of surgery for intramedullary spinal ependymoma. Ann Saudi Med; 2008 Mar-Apr;28(2):109-13
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of surgery for intramedullary spinal ependymoma.
  • BACKGROUND AND OBJECTIVES: Ependymoma is the most frequently encountered intramedullary tumor.
  • This study was designed to define prognostic factors that affect clinical outcome after surgical resection of spinal intramedullary ependymoma.
  • RESULTS: Surgery was performed on 17 patients (14 males, 3 females, mean age of 42+/-15 years) with spinal ependymoma.
  • The cervical spine was the most common tumor location (71%).
  • Total surgical resection of the tumor was achieved in 11 cases (65%).
  • [MeSH-major] Ependymoma / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Monitoring, Intraoperative / methods. Neoplasm Recurrence, Local / epidemiology. Neurologic Examination. Prognosis. Regression Analysis. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398287.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


25. Estrozi B, Queiroga E, Bacchi CE, Faria Soares de Almeida V, Lucas de Carvalho J, Lageman GM, Rosado-de-Christenson M, Suster S: Myxopapillary ependymoma of the posterior mediastinum. Ann Diagn Pathol; 2006 Oct;10(5):283-7
Genetic Alliance. consumer health - Myxopapillary ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxopapillary ependymoma of the posterior mediastinum.
  • Computerized tomography studies revealed a 7 x 6 cm, well circumscribed, noncalcified soft tissue mass with lobular borders abutting the left inferior pulmonary vein and descending aorta.
  • At thoracotomy, the mass was seen to be well circumscribed, focally attached to the pleura but without involvement of lung parenchyma, and situated in the left posterior mediastinum.
  • On histological examination, the lesion showed the classical features of myxopapillary ependymoma.
  • Immunohistochemical studies confirmed this impression by demonstrating strong positivity of the tumor cells for S-100 protein, glial fibrillary acidic protein, and CD99 and negative staining with other differentiation markers.
  • [MeSH-major] Ependymoma / pathology. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / genetics. Antigens, CD / metabolism. Cell Adhesion Molecules / genetics. Cell Adhesion Molecules / metabolism. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / genetics. Glial Fibrillary Acidic Protein / metabolism. Humans. S100 Proteins / genetics. S100 Proteins / metabolism. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979521.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Glial Fibrillary Acidic Protein; 0 / S100 Proteins
  • [Number-of-references] 24
  •  go-up   go-down


26. Spengos K, Vassilopoulou S, Tsivgoulis G, Karachalios G, Vassilopoulos D: Superficial siderosis due to a lumbar ependymoma mimicking adult-onset spinocerebellar ataxia. Clin Neurol Neurosurg; 2007 Oct;109(8):705-7
Genetic Alliance. consumer health - Spinocerebellar Ataxia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial siderosis due to a lumbar ependymoma mimicking adult-onset spinocerebellar ataxia.
  • Superficial siderosis (SS), as a result of chronic subarachnoid haemorrhage and haemosiderin deposition on the leptomeninges and subpial layers of the brain, cerebellum and spinal cord, can cause ataxia, pyramidal tract lesions and hearing deficits.
  • In cases with not pronounced hearing impairment adult-onset spinocerebellar ataxia can be considered as a differential diagnostic alternative.
  • A bleeding lumbar ependymoma was identified as a source of haemorrhage.
  • Surgical tumor resection stopped any further disease progression.
  • [MeSH-major] Ependymoma / complications. Siderosis / diagnosis. Siderosis / etiology. Spinal Cord Neoplasms / complications. Spinocerebellar Ataxias / diagnosis

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Ataxia.
  • Genetic Alliance. consumer health - Siderosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555872.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


27. Moreno L, Bautista FJ, Zacharoulis S: Outcome of teenagers and young adults with ependymoma: the Royal Marsden experience. Childs Nerv Syst; 2009 Sep;25(9):1047-52
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of teenagers and young adults with ependymoma: the Royal Marsden experience.
  • BACKGROUND: The outcome and clinical characteristics of teenagers and young adults (TYA) with ependymoma have not been well documented.
  • We report the Royal Marsden Hospital experience treating TYA with ependymoma.
  • MATERIALS AND METHODS: Sixteen TYA were treated for ependymoma from 1971 to 2004 and are compared to 24 children (not infants) treated in the same period.
  • Up to 56% of patients treated in the paediatric unit received psychosocial support vs. 42.9% of patients treated in the adult unit.
  • DISCUSSION: Ependymoma in adolescents and young adults is an infrequent entity, with perhaps better outcome compared to children.
  • Providing adolescents with ependymoma the appropriate neuro-oncologic care, including access to multidisciplinary teams, full access to clinical trials and age-appropriate neuro-oncologic ancillary support services, remains a challenge.
  • [MeSH-major] Brain Neoplasms / therapy. Ependymoma / therapy
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Neoplasm Recurrence, Local / therapy. Social Support. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2009 Feb;45(3):328-34 [19135358.001]
  • [Cites] Eur J Cancer. 2003 Dec;39(18):2643-50 [14642926.001]
  • [Cites] Oncologist. 2007 Jul;12(7):816-24 [17673613.001]
  • [Cites] Oncologist. 2006 Jun;11(6):590-601 [16794238.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):255-61 [15332330.001]
  • [Cites] CA Cancer J Clin. 2007 Jul-Aug;57(4):242-55 [17626120.001]
  • [Cites] Eur J Cancer. 2003 Dec;39(18):2600-10 [14642922.001]
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1812-6 [4027918.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):830-5 [18728673.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):81-9 [17482475.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v119-27 [14684502.001]
  • [Cites] J Adolesc Health. 1997 Dec;21(6):366-73 [9401854.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v9-13 [14684497.001]
  • [Cites] Cancer. 2006 Oct 1;107(7 Suppl):1645-55 [16906507.001]
  • (PMID = 19533154.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Naruse T, Matsuyama Y, Ishiguro N: Cyclooxygenase-2 expression in ependymoma of the spinal cord. J Neurosurg Spine; 2007 Mar;6(3):240-6
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 expression in ependymoma of the spinal cord.
  • The authors evaluated COX-2 expression in ependymoma of the spinal cord.
  • METHODS: Sixteen ependymoma samples obtained in patients undergoing surgery between 1995 and 2004 were utilized for immunohistochemical studies to evaluate COX-2 and vascular endothelial growth factor (VEGF) expression.
  • Seven (43.8%) of the 16 ependymoma specimens expressed COX-2.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Ependymoma / enzymology. Spinal Cord Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neovascularization, Pathologic / enzymology. Statistics, Nonparametric. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355023.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


29. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, Milde T, Bender S, Wittmann A, Schöttler A, Kulozik AE, Witt O, von Deimling A, Lichter P, Pfister S: Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol; 2010 Jul 1;28(19):3182-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular staging of intracranial ependymoma in children and adults.
  • PURPOSE: The biologic behavior of intracranial ependymoma is unpredictable on the basis of current staging approaches.
  • We aimed at the identification of recurrent genetic aberrations in ependymoma and evaluated their prognostic significance to develop a molecular staging system that could complement current classification criteria.
  • PATIENTS AND METHODS: As a screening cohort, we studied a cohort of 122 patients with ependymoma before standardized therapy by using array-based comparative genomic hybridization.
  • DNA copy-number aberrations identified as possible prognostic markers were validated in an independent cohort of 170 patients with ependymoma by fluorescence in situ hybridization analysis.
  • On the basis of these findings, we developed a molecular staging system comprised of three genetic risk groups, which was then confirmed in the validation cohort.
  • [MeSH-major] Brain Neoplasms / genetics. Comparative Genomic Hybridization / methods. Ependymoma / genetics. In Situ Hybridization, Fluorescence / methods
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Chromosome Aberrations. Cohort Studies. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Female. Gene Deletion. Gene Dosage. Humans. Male. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Rev Neurol. 2010 Aug;6(8):414 [20718114.001]
  • (PMID = 20516456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


30. Mori T, Nomori H, Yoshioka M, Ikeda K, Shibata H, Ohba Y, Yoshimoto K, Iyama K: A case of primary mediastinal ependymoma. Ann Thorac Cardiovasc Surg; 2009 Oct;15(5):332-5
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary mediastinal ependymoma.
  • Computed tomography showed a well-defined spindle-shaped mass 3.4 x 1.0 cm in size in the left paravertebral posterior mediastinum at the Th 3-4 level.
  • The tumor was completely resected via thoracoscopic surgery, which showed no invasion into the surrounding tissue.
  • By means of histological and immunohistochemical examinations, we diagnosed the tumor as ependymoma, and the patient remains alive 59 months after resection.
  • As far as we know, 8 reported cases with primary mediastinal ependymoma have been reported.
  • (1) All patients were adult females;.
  • [MeSH-minor] Back Pain / etiology. Biopsy. Ependymoma / complications. Ependymoma / pathology. Ependymoma / surgery. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Middle Aged. Thoracoscopy. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19901889.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Mukhida K, Asa S, Gentili F, Shannon P: Ependymoma of the pituitary fossa. Case report and review of the literature. J Neurosurg; 2006 Oct;105(4):616-20
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymoma of the pituitary fossa. Case report and review of the literature.
  • The authors describe a case of pituitary fossa ependymoma and discuss its immunohistochemical and ultrastructural characteristics.
  • Magnetic resonance imaging demonstrated a well-demarcated enhancing lesion of the pituitary fossa that was completely resected via a transsphenoidal approach.
  • This is the first study in which investigators examined the appearance of a pituitary ependymoma by using electron microscopy.
  • [MeSH-major] Ependymoma / surgery. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Follow-Up Studies. Humans. Intercellular Junctions / pathology. Intermediate Filaments / pathology. Male. Microscopy, Electron. Nerve Compression Syndromes / diagnosis. Nerve Compression Syndromes / pathology. Nerve Compression Syndromes / surgery. Optic Disk. Optic Nerve Diseases / diagnosis. Optic Nerve Diseases / pathology. Optic Nerve Diseases / surgery. Postoperative Complications / diagnosis

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044567.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


32. Torun F, Tuna H, Bozkurt M, Deda H: Extra-axial ependymoma of posterior fossa extending to the Meckel's cave. Clin Neurol Neurosurg; 2005 Jun;107(4):334-6
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra-axial ependymoma of posterior fossa extending to the Meckel's cave.
  • An extra-axial ependymoma extending from the left cerebellopontine corner to the Meckel's cave is reported.
  • This tumor's infrequent extra-axial location, extension to the Meckel's cave and possible origin are discussed.
  • [MeSH-major] Ependymoma / pathology. Infratentorial Neoplasms / pathology
  • [MeSH-minor] Adult. Cerebellopontine Angle / pathology. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15885395.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


33. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, Minardi S, Janssen I, Giangaspero F, Forni M, Finocchiaro G, Genitori L, Giordano F, Riccardi R, Schoenmakers EF, Massimino M, Sozzi G: Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol; 2006 Nov 20;24(33):5223-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics.
  • PURPOSE: To delineate clinically relevant molecular signatures of intracranial ependymoma.
  • An ependymoma-specific gene expression signature was characterized by the concurrent abnormal expression of developmental and differentiation pathways, including NOTCH and sonic hedgehog signaling.
  • We identified specific differentially imbalanced genomic clones and gene expression signatures significantly associated with tumor location, patient age at disease onset, and retrospective risk for relapse.
  • Integrated genomic and expression profiling allowed us to identify genes of which the expression is deregulated in intracranial ependymoma, such as overexpression of the putative proto-oncogene YAP1 (located at 11q22) and downregulation of the SULT4A1 gene (at 22q13.3).
  • [MeSH-major] Brain Neoplasms / genetics. Ependymoma / genetics. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Adolescent. Adult. Child. Child, Preschool. DNA Methylation. Down-Regulation. Female. Gene Expression Profiling. Humans. In Situ Hybridization, Fluorescence. Infant. Loss of Heterozygosity. Male. Oligonucleotide Array Sequence Analysis. Phosphoproteins / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sulfotransferases / genetics. Up-Regulation

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114655.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Phosphoproteins; 0 / YAP1 (Yes-associated) protein, human; EC 2.8.2 / SULT4A1 protein, human; EC 2.8.2.- / Sulfotransferases
  •  go-up   go-down


34. Ertan Y, Sarsik B, Ozgiray E, Kitis O, Dalbasti T, Akalin T: Pigmented ependymoma with signet-ring cells and Rosenthal fibers: a rare variant of ependymoma. Neuropathology; 2010 Feb 1;30(1):71-5
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented ependymoma with signet-ring cells and Rosenthal fibers: a rare variant of ependymoma.
  • We report a rare case of ependymoma with vacuolar features, signet cells, pigmentation and numerous Rosenthal fibers arising in the fourth ventricle of a 35-year-old woman.
  • The tumor was composed of cells with cytoplasmic vacuoles, signet cells and clear cells.
  • Additionally, some tumor cells contained brown cytoplasmic pigment, which was histochemically compatible with lipofuscin and neuromelanin.
  • On immunohistochemical examination, the tumor cells were positive for S100, glial fibrillary acidic protein and vimentin, and negative for synaptophysin, cytokeratin, neurofilament and HMB45.
  • The case is presented to increase familiarity with these extraordinary variants of ependymoma.
  • [MeSH-major] Brain / pathology. Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Fourth Ventricle / pathology. Pigmentation
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508348.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


35. Vitanovics D, Bálint K, Hanzély Z, Banczerowski P, Afra D: Ependymoma in adults: surgery, reoperation and radiotherapy for survival. Pathol Oncol Res; 2010 Mar;16(1):93-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymoma in adults: surgery, reoperation and radiotherapy for survival.
  • PURPOSE: to retrospectively determine the long-term outcome of adult intracranial ependymoma patients treated with surgery, reoperation, and postoperative radiation therapy.
  • Forty patients had World Health Organization (WHO) Grade II ependymoma, and 21 patients had Grade III ependymoma.
  • A statistically significant effect on prognosis was observed with WHO tumour grade as well as with MIB-1 labelling index.
  • CONCLUSION: In our experience the use of radiotherapy in adult, intracranial WHO Grade II ependymoma patients had no significant effect on prognosis.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / therapy. Ependymoma / mortality. Ependymoma / therapy. Neurosurgical Procedures
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Radiotherapy. Reoperation. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19728165.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


36. Preusser M, Heinzl H, Gelpi E, Höftberger R, Fischer I, Pipp I, Milenkovic I, Wöhrer A, Popovici F, Wolfsberger S, Hainfellner JA: Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology; 2008 Jul;53(1):39-47
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker.
  • AIMS: The Ki67 tumour cell proliferation index is an independent prognostic factor in ependymoma patients.
  • To this end, the aim was to analyse systematically inter- and intraobserver agreement and reproducibility of the prognostic impact of the Ki67 index in intracranial ependymoma.
  • METHODS AND RESULTS: The study cohort contained 78 cases of intracranial ependymoma.
  • CONCLUSIONS: Our data show that the Ki67 index in intracranial ependymoma is a reproducible and robust prognostic factor and can be considered a promising histopathological candidate biomarker.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Brain Neoplasms / pathology. Ependymoma / chemistry. Ependymoma / pathology. Ki-67 Antigen / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Count. Cell Proliferation. Child. Child, Preschool. Humans. Immunohistochemistry. Infant. Middle Aged. Observer Variation. Prognosis. Reproducibility of Results. Retrospective Studies

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613924.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


37. Schroeder TM, Chintagumpala M, Okcu MF, Chiu JK, Teh BS, Woo SY, Paulino AC: Intensity-modulated radiation therapy in childhood ependymoma. Int J Radiat Oncol Biol Phys; 2008 Jul 15;71(4):987-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy in childhood ependymoma.
  • PURPOSE: To determine the patterns of failure after intensity-modulated radiation therapy (IMRT) for localized intracranial ependymoma.
  • METHODS AND MATERIALS: From 1994 to 2005, 22 children with pathologically proven, localized, intracranial ependymoma were treated with adjuvant IMRT.
  • Of the patients, 12 (55%) had an infratentorial tumor and 14 (64%) had anaplastic histology.
  • The clinical target volume encompassed the tumor bed and any residual disease plus margin (median dose 54 Gy).
  • At last follow-up, no patient had developed visual loss, brain necrosis, myelitis, or a second malignancy.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Ependymoma / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. Humans. Infant. Male. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18258381.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Whittemore DE, Grondahl RE, Wong K: Primary extraneural myxopapillary ependymoma of the broad ligament. Arch Pathol Lab Med; 2005 Oct;129(10):1338-42
Genetic Alliance. consumer health - Myxopapillary ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extraneural myxopapillary ependymoma of the broad ligament.
  • Here we describe a myxopapillary ependymoma of the broad ligament in a 22-year-old woman, which may be the first tumor of this type to be reported in this location.
  • Identification of perivascular ependymal rosettes, ependymal canals, vimentin and glial fibrillary acidic protein immunoreactivity, cytochemical staining of blepharoplasts or terminal bars by phosphotungstic acid hematoxylin, and presence of multiple foci of myxoid degeneration among the ependymal rosettes characterized a myxopapillary ependymoma.
  • [MeSH-major] Broad Ligament / pathology. Ependymoma / pathology. Genital Neoplasms, Female / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Fibroma / diagnosis. Glial Fibrillary Acidic Protein / analysis. Granulosa Cell Tumor / diagnosis. Humans. Treatment Outcome. Vimentin / analysis

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16196528.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin
  •  go-up   go-down


39. Hegyi L, Peston D, Theodorou M, Moss J, Olver J, Roncaroli F: Primary glial tumor of the retina with features of myxopapillary ependymoma. Am J Surg Pathol; 2005 Oct;29(10):1404-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary glial tumor of the retina with features of myxopapillary ependymoma.
  • We report a primary retinal tumor with features of myxopapillary ependymoma.
  • Histologically, the retina was replaced by a tumor composed of spindle cells with fibrillary cytoplasm and round to ovoid nuclei forming fascicles, perivascular pseudorosettes, microcysts, and deposition of extracellular mucins.
  • Tumor cells expressed GFAP and S-100 and to lesser extent carbonic anhydrase II.
  • As control cases, we also investigated expression of EMA and carbonic anhydrase II in an ocular globe with retinal gliosis and three cases of myxopapillary ependymoma of the cauda equina.
  • The lesion described here represents the first example of retinal tumor with features of myxopapillary ependymoma.
  • [MeSH-major] Ependymoma / pathology. Glioma / pathology. Retinal Neoplasms / pathology
  • [MeSH-minor] Adult. Carbonic Anhydrase II / biosynthesis. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Mucin-1 / biosynthesis

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Myxopapillary ependymoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160486.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucin-1; EC 4.2.1.- / Carbonic Anhydrase II
  •  go-up   go-down


40. Jain A, Rishi A, Suri V, Garg A, Sharma MC, Sarkar C, Sharma BS: Recurrent ependymoma with cartilaginous metaplasia in an adult: report of a rare case and review of literature. Clin Neuropathol; 2009 Mar-Apr;28(2):101-4
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent ependymoma with cartilaginous metaplasia in an adult: report of a rare case and review of literature.
  • The present report discusses an unusual case of ependymoma with cartilaginous metaplasia in a 21-year-old male.
  • [MeSH-major] Cartilage / pathology. Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Neoplasm Recurrence, Local
  • [MeSH-minor] Brain / pathology. Humans. Magnetic Resonance Imaging. Male. Metaplasia. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19353841.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 16
  •  go-up   go-down


41. Vajtai I, Kuhlen D, Kappeler A, Mariani L, Zimmermann A, Paulus W: Rapid spontaneous malignant progression of supratentorial tanycytic ependymoma with sarcomatous features - "Ependymosarcoma". Pathol Res Pract; 2010 Jul 15;206(7):493-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid spontaneous malignant progression of supratentorial tanycytic ependymoma with sarcomatous features - "Ependymosarcoma".
  • By analogy to gliosarcoma, the term "ependymosarcoma" has recently been coined to thematize the rare phenomenon of a malignant mesenchymal component arising within an ependymoma.
  • We report on an example of this paradigm, involving tanycytic ependymoma as the host tumor in a 40-year-old female who underwent two tumor extirpation procedures at one-year interval.
  • Microscopically, the tumor consisted of solid, wavy fascicles of elongated cells that were occasionally interrupted by vague perivascular pseudorosettes.
  • A histological diagnosis of tanycytic ependymoma (WHO grade II) was rendered, and no adjuvant therapy given.
  • Histology showed a biphasic glial-sarcomatous architecture with remnants of the original ependymoma now displaying hypercellularity and atypical - yet not frankly anaplastic - features.
  • To the best of our knowledge, this is the first documentation of tanycytic ependymoma undergoing malignant transformation, one driven by a highly anaplastic mesenchymal component, corresponding to "ependymosarcoma".
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Ependymoma / pathology. Gliosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Immunophenotyping. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19853384.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Arai T, Tani S, Isoshima A, Nagashima H, Joki T, Takahashi-Fujigasaki J, Abe T: [Intraoperative photodynamic diagnosis for spinal ependymoma using 5-aminolevulinic acid: technical note]. No Shinkei Geka; 2006 Aug;34(8):811-7
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraoperative photodynamic diagnosis for spinal ependymoma using 5-aminolevulinic acid: technical note].
  • OBJECTIVE: The fluorescence-guided resection using 5-aminolevulinic acid (5-ALA) is a well established method for the treatment of brain tumor, especially malignant glioma.
  • However, there is no report on photodynamic diagnosis (PDD) for spinal tumor.
  • In the present study, we evaluated the usefulness of PDD for spinal ependymoma using 5-ALA.
  • METHODS: Three patients with spinal ependymoma received oral doses of 5-ALA (20 mg/kg body weight) 2 hours before anesthesia induction.
  • Residual fluorescent samples taken from the tumor cavity were examined histologically RESULTS: Fluorescence peaked at 636nm in the removed tumors in all cases.
  • Fluorescent tissue tended to exist at the cranial and caudal portion in the tumor cavity or around the anterior median fissure.
  • The residual fluorescent tissue was not detected after removal of the tumor in case 1.
  • The residual fluorescent tissue was composed of tumor cells and ependymal lining in case 2 or the infiltrated inflammatory cells and vascular endothelial cells in case 3.
  • Postoperative magnetic resonance (MR) imaging showed no residual tumor in any of the cases.
  • CONCLUSION: The results of this study indicate the usefulness of 5-ALA-induced tumor fluorescence in guiding resection of spinal ependymoma.
  • 5-ALA-induced porphyrin fluorescence may label spinal ependymomas easily and clearly enough to enhance the completeness of tumor removal.
  • [MeSH-major] Aminolevulinic Acid. Ependymoma / diagnosis. Photosensitizing Agents. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Fluorescence. Humans. Intraoperative Period. Lighting. Magnetic Resonance Imaging. Male. Middle Aged. Porphyrins. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910494.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


43. Satti M, Firoze M, Malaker K, Hussain M, Maniyar I: Mediastinal myxopapillary ependymoma primary or late metastases of paracoccygeal ependymoma: a case report. Ann Diagn Pathol; 2005 Aug;9(4):215-8
Genetic Alliance. consumer health - Myxopapillary ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal myxopapillary ependymoma primary or late metastases of paracoccygeal ependymoma: a case report.
  • A computed tomographic scan of the chest showed a huge anterior mediastinal mass, and pathological examination of a mediastinoscopic needle biopsy revealed typical myxopapillary ependymoma, an extremely unusual diagnosis at this site.
  • Review of the histology of the excised mass showed a myxopapillary ependymoma, similar to current histology.
  • [MeSH-major] Buttocks / pathology. Ependymoma / secondary. Mediastinal Neoplasms / secondary. Sacrococcygeal Region / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084455.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Kurimoto M, Nagai S, Hamada H, Tsuboi Y, Hayashi N, Kubota T, Endo S: Malignant transformation of supratentorial clear cell ependymoma. Neuropathology; 2009 Jun;29(3):299-302
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of supratentorial clear cell ependymoma.
  • Recurrence of clear cell ependymoma is not a rare condition, but malignant transformation of clear cell ependymoma has not yet been well presented.
  • A brain tumor in the left frontal premotor area was removed and an initial pathological diagnosis of oligodendroglioma was made.
  • The tumor recurred 4 months later, and reoperation of the tumor and adjuvant local radiotherapy were performed.
  • At this time, the tumor had an ultrastructural appearance compatible with ependymoma.
  • The autopsy specimens resembled a feature of glioblastoma but the tumor was sharply demarcated from the surrounding parenchyma.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Brain / pathology. Brain / ultrastructure. Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647267.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


45. Ferroli P, Russo A, Albanese E, Tringali G, Broggi G: Gravity-aided trans-falcine removal of a contralateral subcortical ependymoma. Acta Neurochir (Wien); 2007 Nov;149(11):1147-50; discussion 1150
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gravity-aided trans-falcine removal of a contralateral subcortical ependymoma.
  • We report a 32-year-old woman with an ependymoma of the medial surface of the left Rolandic area that was completely removed through a contralateral gravity-aided, image-guided transfalcine approach.
  • [MeSH-major] Brain Neoplasms / surgery. Craniotomy / methods. Ependymoma / surgery. Microsurgery / methods. Neuronavigation / methods. Temporal Lobe / surgery
  • [MeSH-minor] Adult. Dominance, Cerebral / physiology. Female. Follow-Up Studies. Gravitation. Humans. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17712517.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


46. Luther N, Souweidane MM: Neuroendoscopic resection of posterior third ventricular ependymoma. Case report. Neurosurg Focus; 2005 Jun 15;18(6A):E3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendoscopic resection of posterior third ventricular ependymoma. Case report.
  • The practice of neuroendoscopy in the definitive management of cystic tumors and hydrocephalus has been well established.
  • The authors present the case of a 31-year-old woman in whom endoscopic resection of a posterior third ventricular ependymoma was successfully accomplished.
  • [MeSH-major] Cerebral Ventricle Neoplasms / surgery. Ependymoma / surgery. Neuroendoscopy / methods. Third Ventricle / surgery. Ventriculostomy / methods
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048289.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Sparaco M, Morelli L, Piscioli I, Donato S, Catalucci A, Licci S: Primary myxopapillary ependymoma of the cerebellopontine angle: report of a case. Neurosurg Rev; 2009 Apr;32(2):241-4; discussion 244
Genetic Alliance. consumer health - Myxopapillary ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary myxopapillary ependymoma of the cerebellopontine angle: report of a case.
  • Myxopapillary ependymoma is a rare variant of ependymoma, almost exclusively occurring in the region of the cauda equina and filum terminale.
  • We describe a myxopapillary ependymoma located in the left cerebellopontine angle of a young man suffering from peripheral vertigo and left sensorineural hearing loss for years.
  • Microscopic examination showed histological and immunohistochemical features consistent with a diagnosis of myxopapillary ependymoma.
  • To the best of our knowledge, this is the first case of primary intracranial myxopapillary ependymoma described in this location.
  • [MeSH-major] Cerebellar Neoplasms / diagnosis. Cerebellopontine Angle. Ependymoma / diagnosis
  • [MeSH-minor] Adult. Hearing Loss, Sensorineural / etiology. Humans. Magnetic Resonance Imaging. Male. Recovery of Function. Tomography, X-Ray Computed. Treatment Outcome. Vertigo / etiology

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1977 Aug;40(2):907-15 [890671.001]
  • [Cites] Histopathology. 1999 Apr;34(4):331-41 [10231401.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Jun;66(6):768-71 [10329752.001]
  • [Cites] Acta Neurochir (Wien). 2006 Mar;148(3):343-6; discussion 346 [16362177.001]
  • [Cites] Cancer. 1966 Apr;19(4):585-90 [5933582.001]
  • [Cites] J Neurooncol. 1993 Mar;15(3):251-6 [8360710.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):111-5 [8699232.001]
  • [Cites] Mod Pathol. 1997 Apr;10(4):304-10 [9110291.001]
  • [Cites] J Neuropathol Exp Neurol. 1948 Oct;7(4):349-67 [18889208.001]
  • [Cites] Neurol Med Chir (Tokyo). 1997 Oct;37(10):762-5 [9362137.001]
  • [Cites] Acta Radiol. 2004 May;45(3):344-7 [15239433.001]
  • [Cites] Folia Neuropathol. 2003;41(1):51-7 [12862397.001]
  • [Cites] Clin Neuropathol. 2004 Mar-Apr;23(2):53-8 [15074578.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):883-93 [4016681.001]
  • [Cites] Hum Pathol. 1992 Aug;23(8):960-2 [1644442.001]
  • [Cites] Am J Otol. 1990 May;11(3):216-32 [2188512.001]
  • [Cites] Curr Neurol Neurosci Rep. 2003 May;3(3):193-9 [12691623.001]
  • [Cites] Neurosurgery. 1993 Nov;33(5):824-30; discussion 830-1 [7903434.001]
  • [Cites] Neurology. 1953 Jan;3(1):1-15 [13013493.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):807-22 [9161731.001]
  • [Cites] Acta Pathol Jpn. 1983 Sep;33(5):1017-25 [6359815.001]
  • [Cites] Clin Neurol Neurosurg. 2006 Feb;108(2):211-4 [16412846.001]
  • (PMID = 18758834.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


48. Adamson DC, Cummings TJ, Friedman AH: Myxopapillary ependymoma and fatty filum in an adult with tethered cord syndrome: a shared embryological lesion? Case report. Neurosurgery; 2005 Aug;57(2):E373; discussion E373
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxopapillary ependymoma and fatty filum in an adult with tethered cord syndrome: a shared embryological lesion? Case report.
  • OBJECTIVE AND IMPORTANCE: Myxopapillary ependymoma and fatty fila are traditionally thought to arise via completely different pathophysiologies.
  • Magnetic resonance imaging revealed lesions in the area of the conus medullaris consistent with a myxopapillary ependymoma and fatty filum.
  • CONCLUSION: We report an unusual case of a myxopapillary ependymoma coexisting with a fatty filum in an adult patient.
  • [MeSH-major] Cauda Equina / pathology. Ependymoma / complications. Lipoma / complications. Neural Tube Defects / complications. Spinal Cord Neoplasms / complications


49. Shintaku M, Nagata N, Itoh H: Tanycytic ependymoma of the spinal cord with anaplastic cytological features. Brain Tumor Pathol; 2009;26(1):7-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tanycytic ependymoma of the spinal cord with anaplastic cytological features.
  • In a 43-year-old man, an intramedullary spinal cord tumor spreading from the level of the T2 to T5 vertebrae was subtotally resected.
  • The tumor predominantly consisted of a fascicular proliferation of spindle cells having bland nuclei and bipolar, long cytoplasmic processes, and a few perivascular pseudo-rosettes were found.
  • This is the first documentation of tanycytic ependymoma in which tumor cells showed anaplastic cytological features.
  • [MeSH-major] Ependymoma / pathology. Spinal Cord / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Anaplasia / pathology. Humans. Immunohistochemistry. Ki-67 Antigen / immunology. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Anaplastic Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408091.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


50. Sangoi AR, Lim M, Dulai M, Vogel H, Chang S: Suprasellar giant cell ependymoma: a rare neoplasm in a unique location. Hum Pathol; 2008 Sep;39(9):1396-401
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suprasellar giant cell ependymoma: a rare neoplasm in a unique location.
  • Giant cell ependymoma, a rare ependymal subtype only recently recognized as a diagnostic entity in the last decade, demonstrates pleomorphic giant cells admixed with features of typical ependymoma.
  • We describe the presentation and pertinent radiologic, histologic, immunologic, and ultrastructural findings in conjunction with relevant clinical implications of the first reported case of a suprasellar giant cell ependymoma occurring in a 34-year-old female 7 years after an initial diagnosis of a medullary ependymoma with rare atypical giant cells, a potential tumor seeding culprit.
  • [MeSH-major] Ependymoma / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602668.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Liu AK, Foreman NK, Gaspar LE, Trinidad E, Handler MH: Maximally safe resection followed by hypofractionated re-irradiation for locally recurrent ependymoma in children. Pediatr Blood Cancer; 2009 Jul;52(7):804-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maximally safe resection followed by hypofractionated re-irradiation for locally recurrent ependymoma in children.
  • BACKGROUND: Treatment failure in children with ependymoma is relatively common, with the majority of events consisting of local failure.
  • To minimize the duration of therapy, we chose a hypofractionated regimen that has been shown to be well tolerated in adult patients.
  • PROCEDURE: We performed a review of the experience at the Children's Hospital in Denver and at the Department of Radiation Oncology at the University of Colorado Denver from 1995 to 2008 with hypofractionated re-irradiation after maximally safe resection in children with locally recurrent ependymoma.
  • RESULTS: Six children with locally recurrent ependymoma were seen in that time period.
  • CONCLUSIONS: Hypofractionated re-irradiation after resection for locally recurrent ependymoma is well tolerated.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Ependymoma / radiotherapy. Ependymoma / surgery. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery


52. Mizuno J, Nakagawa H, Inoue T, Kondo S, Hara K, Hashizume Y: Signet-ring cell ependymoma with intratumoral hemorrhage in the medulla oblongata. J Clin Neurosci; 2005 Aug;12(6):711-4
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell ependymoma with intratumoral hemorrhage in the medulla oblongata.
  • We report a case of signet-ring cell ependymoma of the medulla oblongata.
  • However, the final paraffin section showed an ependymoma with signet-ring cells.
  • Signet-ring cell ependymoma must be included in the differential diagnosis of metastatic carcinoma to the central nervous system.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Carcinoma, Signet Ring Cell / pathology. Ependymoma / pathology. Intracranial Hemorrhages / pathology. Medulla Oblongata
  • [MeSH-minor] Adult. Child. Child, Preschool. Female. Humans. Immunohistochemistry / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged. Mucin-1 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115557.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Mucin-1
  •  go-up   go-down


53. Schuurmans M, Vanneste JA, Verstegen MJ, van Furth WR: Spinal extramedullary anaplastic ependymoma with spinal and intracranial metastases. J Neurooncol; 2006 Aug;79(1):57-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal extramedullary anaplastic ependymoma with spinal and intracranial metastases.
  • Magnetic resonance imaging (MRI) of the cervical spine revealed an extramedullary tumor with severe spinal cord compression.
  • During surgery an intradural extramedullary tumor was found.
  • Further imaging showed a second lumbar spinal tumor.
  • [MeSH-major] Brain Neoplasms / secondary. Ependymoma / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Cervical Vertebrae. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Lumbar Vertebrae. Magnetic Resonance Imaging. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Anaplastic Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614942.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / S100 Proteins
  •  go-up   go-down


54. Cui Y, Zhao JZ: [Expression of epidermal growth factor receptor and Ki-67 antigen in brain ependymoma and the correlation between them]. Zhonghua Yi Xue Za Zhi; 2008 Dec 23;88(47):3356-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of epidermal growth factor receptor and Ki-67 antigen in brain ependymoma and the correlation between them].
  • OBJECTIVE: To study the expression of epidermal growth factor receptor (EGFR) and Ki-67 antigen in human brain ependymoma and the correlation between them.
  • METHODS: Immunohistochemistry was used to detect the expression of EGFR and Ki-67 antigen in 40 specimens of brain ependymoma, 8 specimens of normal brain tissues, and 8 specimens of glioblastoma, all obtained during operation.
  • RESULTS: The EGFR positive rate of the III - IV grade ependymoma tissues was 75%, significantly higher than that of the grade I - II grade ependymoma tissues (25%, P < 0.05).
  • The EGFR positive rate of the recurrent ependymoma tissues (5/6) was significantly higher than that of the primary ependymoma tissues (9/34, P < 0.05).
  • The positive rate of Ki-67 L1 in the III - IV grade ependymoma tissues was (9.5 +/- 5.6)%, significantly higher than that in the grade I - II grade ependymoma tissues [(2.2 +/- 1.4)%, P < 0.05)].
  • The positivity of EGFR was positively correlated with the grade level of ependymoma and Ki-67 L1 positivity (both P < 0.01).
  • CONCLUSION: EGFR expression positive rate increases with tumor grading.
  • The positive rate of recurrent ependymoma is higher than that of the primary ependymoma.
  • [MeSH-major] Brain Neoplasms / metabolism. Ependymoma / metabolism. Ki-67 Antigen / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19257969.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


55. Shu HK, Sall WF, Maity A, Tochner ZA, Janss AJ, Belasco JB, Rorke-Adams LB, Phillips PC, Sutton LN, Fisher MJ: Childhood intracranial ependymoma: twenty-year experience from a single institution. Cancer; 2007 Jul 15;110(2):432-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood intracranial ependymoma: twenty-year experience from a single institution.
  • BACKGROUND: Because few large studies of pediatric ependymoma treatment are available, the authors believed that a retrospective review of treatment outcomes from a single institution would yield potentially valuable information regarding potential prognostic factors.
  • METHODS: Medical records were reviews of patients with intracranial ependymoma who received their initial treatment at the Children's Hospital of Philadelphia (CHOP)/Hospital of the University of Pennsylvania (HUP) between January 1980 and December 2000.
  • CONCLUSIONS: In this study of patients with pediatric intracranial ependymoma, OS and PFS rates were concordant with the rates published in other modern series.
  • Tumor extension to the cervical spine was identified as a predictor for failure outside of the primary site.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Prognosis. Survival Analysis. Treatment Outcome


56. Yan X, Cheng X, Liu J, Luo D, He X, Chen F, Qin C, Wang Y: Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma. Clin Invest Med; 2008;31(4):E206-11
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma.
  • Tissue samples obtained from 15 patients with brain contusion were used as control.
  • Positive cell rates were 2.65+/-0.83 % in the low-grade, 9.63+/-0.08 % in the mid-grade, and 28.41+/-0.71 % in the high-grade ependymoma groups.
  • In the mid-grade ependymoma group eNOS was expressed moderately in 10 cases and intensely in 15.
  • CONCLUSION: Ki-67 and eNOS expression in intracranial ependymoma tissue was associated with the histopathological grade and malignant degree.
  • [MeSH-major] Brain Neoplasms. Ependymoma. Gene Expression Regulation / drug effects. Ki-67 Antigen / therapeutic use. Nitric Oxide Synthase Type III / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682044.001).
  • [ISSN] 1488-2353
  • [Journal-full-title] Clinical and investigative medicine. Médecine clinique et experimentale
  • [ISO-abbreviation] Clin Invest Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Ki-67 Antigen; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  •  go-up   go-down


57. Gallia GL, Burger PC, Suk I, Bagley CA, Wolinsky JP, Garonzik IM, Gokaslan ZL: Concomitant conus medullaris ependymoma and filum terminale lipoma: case report. Neurosurgery; 2006 Jun;58(6):E1214; discussion E1214
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant conus medullaris ependymoma and filum terminale lipoma: case report.
  • In this report, we describe the clinical presentation, radiographic findings, operative details, and pathological features of a patient with a conus medullaris ependymoma and a filum terminale lipoma.
  • Histopathological examination demonstrated a conus medullaris ependymoma and filum terminale lipoma.
  • In this report, we describe a patient with a concomitant conus medullaris ependymoma and filum terminale lipoma.
  • [MeSH-major] Cauda Equina / surgery. Ependymoma / surgery. Lipoma / surgery. Lumbar Vertebrae / surgery. Neoplasms, Multiple Primary / surgery. Peripheral Nervous System Neoplasms / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Laminectomy. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16723873.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Szpak GM, Lewandowska E, Schmidt-Sidor B, Pasennik E, Modzelewska J, Stepień T, Zdaniuk G, Kulczycki J, Wierzba-Bobrowicz T: Giant cell ependymoma of the spinal cord and fourth ventricle coexisting with syringomyelia. Folia Neuropathol; 2008;46(3):220-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell ependymoma of the spinal cord and fourth ventricle coexisting with syringomyelia.
  • This report presents a case of widespread intramedullary giant cell ependymoma arising from the central canal of the C4 segment of the spinal cord in a 28-year-old man admitted to hospital with tetraplegia and signs of increased intracranial pressure, eight months after surgical spinal cervical decompression without tetraplegia improvement.
  • This slow-growing ependymoma of low-grade malignancy exhibited unusual morphology as well as degenerative and ischaemic changes.
  • The morphological diagnostic criteria of unusual giant-cell variant of ependymoma and tumour-related syringomyelia in adults are discussed, based on the presented case and a review of the literature.

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Syringomyelia.
  • MedlinePlus Health Information. consumer health - Syringomyelia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18825598.001).
  • [ISSN] 1641-4640
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


59. Hwang HJ, Sohn JH, Han SJ, Kim TS, Lee YS, Kim JH: Multi-disciplinary treatment of a rare pelvic cavity ependymoma. Yonsei Med J; 2007 Aug 31;48(4):719-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-disciplinary treatment of a rare pelvic cavity ependymoma.
  • Here, we present an ependymoma arising from the pelvic cavity.
  • Histologically, the tumor was characterized by compact columnar neoplastic cells divided by fibrovascular septae.
  • The tumor was thus diagnosed as an ependymoma arising from the pelvic cavity.
  • This is a rare case of extraneural ependymoma for which an in vitro chemosensitivity test was critical in determining the multidisciplinary approach for treatment.
  • [MeSH-major] Ependymoma / pathology. Pelvic Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Ependymoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2001 Feb;33(1):26-9 [11280604.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):421-3 [12946033.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3618-30 [15289487.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):203-9 [6703196.001]
  • [Cites] Mayo Clin Proc. 1992 Apr;67(4):373-8 [1548954.001]
  • [Cites] Arch Pathol Lab Med. 1985 Mar;109(3):291-3 [3838461.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):62-8 [3522133.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2565-71 [2684388.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):20-7 [1985717.001]
  • [Cites] Hum Pathol. 1984 Jul;15(7):632-8 [6204919.001]
  • (PMID = 17722249.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628065
  •  go-up   go-down


60. Kano T, Ikota H, Wada H, Iwasa S, Kurosaki S: A case of an anaplastic ependymoma with gliosarcomatous components. Brain Tumor Pathol; 2009;26(1):11-7
Genetic Alliance. consumer health - Anaplastic Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of an anaplastic ependymoma with gliosarcomatous components.
  • The tumor was removed, and pathological studies revealed a cerebellar astrocytoma corresponding to World Health Organization grade II.
  • When she was 35 years old, or 6 years after the surgery, magnetic resonance imaging revealed a recurrence of the tumor in the right cerebellum, and subtotal removal of the recurrent tumor was performed.
  • Pathological studies revealed a mixed glioblastoma multiforme and anaplastic ependymoma.
  • Thereafter, at 39 years of age, or 4 years after radiation therapy, magnetic resonance imaging again revealed a recurrence of the tumor, which was heterogeneously enhanced with gadoliniumdiethylenetriamine pentaacetic acid in the right cerebellum.
  • Subtotal removal of the tumor was performed; pathological studies revealed an anaplastic ependymoma with sarcomatous components.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Ependymoma / pathology. Gliosarcoma / pathology
  • [MeSH-minor] Adult. Astrocytoma / pathology. Astrocytoma / surgery. Female. Glial Fibrillary Acidic Protein / metabolism. Headache / etiology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Paraffin Embedding. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408092.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


61. Merchant TE, Kiehna EN, Li C, Xiong X, Mulhern RK: Radiation dosimetry predicts IQ after conformal radiation therapy in pediatric patients with localized ependymoma. Int J Radiat Oncol Biol Phys; 2005 Dec 01;63(5):1546-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dosimetry predicts IQ after conformal radiation therapy in pediatric patients with localized ependymoma.
  • PURPOSE: To assess the effects of radiation dose-volume distribution on the trajectory of IQ development after conformal radiation therapy (CRT) in pediatric patients with ependymoma.
  • METHODS AND MATERIALS: The study included 88 patients (median age, 2.8 years +/- 4.5 years) with localized ependymoma who received CRT (54-59.4 Gy) that used a 1-cm margin on the postoperative tumor bed.
  • Differential dose-volume histograms (DVH) were derived for total-brain, supratentorial-brain, and right and left temporal-lobe volumes.
  • For all patients, IQ was best estimated by age (years) at CRT; percent volume of the supratentorial brain that received doses between 0 and 20 Gy, 20 and 40 Gy, and 40 and 65 Gy; and time (months) after CRT.
  • CONCLUSION: Radiation dosimetry can be used to predict IQ after CRT in patients with localized ependymoma.
  • The specificity of models may be enhanced by grouping according to tumor location.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Ependymoma / radiotherapy. Intelligence / radiation effects. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adolescent. Adult. Age Factors. Algorithms. Child. Child, Preschool. Female. Humans. Infant. Intelligence Tests. Male. Prospective Studies. Radiotherapy Dosage. Time Factors

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115736.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Gilhuis HJ, van der Laak JA, Pomp J, Kappelle AC, Gijtenbeek JM, Wesseling P: Three-dimensional (3D) reconstruction and quantitative analysis of the microvasculature in medulloblastoma and ependymoma subtypes. Angiogenesis; 2006;9(4):201-8
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional (3D) reconstruction and quantitative analysis of the microvasculature in medulloblastoma and ependymoma subtypes.
  • In the World Health Organisation (WHO) classification of tumours of the nervous system, four main histopathological subtypes of medulloblastomas (classic medulloblastoma, desmoplastic medulloblastoma, medulloblastoma with extensive nodularity and advanced neuronal differentiation and large cell/anaplastic medulloblastoma) as well as of ependymal tumours (low-grade ependymoma, anaplastic ependymoma, myxopapillary ependymoma and subependymoma) are recognised.
  • Three-dimensional analysis of ependymal tumours showed that low-grade ependymoma had larger but fewer vessels compared to anaplastic ependymoma, while myxopapillary ependymoma had a complex, heterogeneous pattern of vessels and subependymoma few but regular vessels.
  • In ependymal tumours, the highest values for vessel number, vessel area and vessel perimeter were found in anaplastic ependymoma and the lowest values in subependymoma.
  • [MeSH-major] Cerebellar Neoplasms / blood supply. Ependymoma / blood supply. Medulloblastoma / blood supply. Models, Biological
  • [MeSH-minor] Adult. Animals. Humans. Mice. Microcirculation / physiology

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17109194.001).
  • [ISSN] 0969-6970
  • [Journal-full-title] Angiogenesis
  • [ISO-abbreviation] Angiogenesis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


63. Wahab SH, Simpson JR, Michalski JM, Mansur DB: Long term outcome with post-operative radiation therapy for spinal canal ependymoma. J Neurooncol; 2007 May;83(1):85-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term outcome with post-operative radiation therapy for spinal canal ependymoma.
  • PURPOSE: A retrospective study was performed to evaluate the long term efficacy and safety of post-operative radiation therapy in the management of spinal canal ependymoma at our institution.
  • METHODS AND MATERIALS: Between 1954 and 1997, 22 patients with spinal canal ependymoma were treated with post-operative radiotherapy at our institution.
  • All patients underwent open biopsy with histologic diagnosis: 13 patients (59%) had ependymoma (WHO Grade II) and 9 patients (41%) had myxopapillary ependymoma (WHO Grade I).
  • The median tumor size was 4.0 cm (range 1.5-15.0 cm).
  • There was no significant correlation between tumor size and OS.
  • CONCLUSIONS: Post-operative radiation after subtotal resection is safe and offers durable tumor control and long term patient survival.
  • [MeSH-major] Ependymoma / radiotherapy. Ependymoma / surgery. Spinal Canal. Spinal Cord Neoplasms / radiotherapy. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206474.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


64. O'Shaughnessy J, Bussières A: Subtle clinical signs of a spinal cord ependymoma at the cervicothoracic level in an adult: a case report. J Can Chiropr Assoc; 2006 Dec;50(4):244-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtle clinical signs of a spinal cord ependymoma at the cervicothoracic level in an adult: a case report.
  • A magnetic resonance imaging (MRI) study was performed and revealed an expansive intramedullary lesion between C6 and T1 suggesting a differential diagnosis of spinal cord ependymoma or astrocytoma.
  • Pathological report confirmed a diagnosis of ependymoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spinal Cord. 1999 Nov;37(11):753-9 [10578245.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):270-85 [12761644.001]
  • [Cites] Neurosurgery. 1992 Feb;30(2):202-7 [1545888.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):523-32 [2319309.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):842-5 [2585075.001]
  • [Cites] Surg Neurol. 1988 Apr;29(4):271-81 [3353839.001]
  • [Cites] J Neurooncol. 1996 Aug;29(2):183-8 [8858524.001]
  • [Cites] Cancer. 1977 Aug;40(2):907-15 [890671.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):845-50 [9531369.001]
  • [Cites] Childs Nerv Syst. 1998 Aug;14(8):357-61 [9753400.001]
  • [Cites] Br J Neurosurg. 1997 Dec;11(6):542-53 [11013626.001]
  • [Cites] J Neurooncol. 2000 May;47(3):211-8 [11016737.001]
  • [Cites] Korean J Radiol. 2002 Oct-Dec;3(4):219-28 [12514338.001]
  • (PMID = 17549184.001).
  • [ISSN] 0008-3194
  • [Journal-full-title] The Journal of the Canadian Chiropractic Association
  • [ISO-abbreviation] J Can Chiropr Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC1840009
  •  go-up   go-down


65. Lukashova-v Zangen I, Kneitz S, Monoranu CM, Rutkowski S, Hinkes B, Vince GH, Huang B, Roggendorf W: Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol; 2007 Mar;113(3):325-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival.
  • Ependymomas are primary tumors of the central nervous system that typically originate from the walls of the cerebral ventricles or from the spinal canal.
  • There was no relationship between expression profiles and tumor grade, patient age, and patient gender.
  • Our results provide insight into specific molecular events underlying ependymoma tumorigenesis and may contribute to more accurate diagnosis and prediction of clinical outcome.
  • [MeSH-major] Cell Proliferation. Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / mortality. Ependymoma / genetics. Ependymoma / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Gene Expression / physiology. Gene Expression Profiling / methods. Humans. Infant. Infant, Newborn. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ependymoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17265049.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


66. Terasaki M, Uchikado H, Takeuchi Y, Shigemori M: Minimally invasive management of ependymoma of the aqueduct of Sylvius: therapeutic considerations and management. Minim Invasive Neurosurg; 2005 Dec;48(6):322-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive management of ependymoma of the aqueduct of Sylvius: therapeutic considerations and management.
  • A major concern in the neuroendoscopic approach to an intraventricular tumor is the histological confirmation from a limited biopsy.
  • However, the effort to excise the whole bulk of the tumor should be made for the minimally invasive management of selected intraventricular tumors.
  • The case of an adult male with focal aqueductal ependymoma who presented with the clinical syndrome of hydrocephalus is reported.
  • This may be of particular interest because it represents the first case of aqueductal ependymoma that has been successfully treated with endoscopic surgery.
  • [MeSH-major] Brain Neoplasms / surgery. Cerebral Aqueduct / pathology. Cerebral Aqueduct / surgery. Ependymoma / surgery. Neuroendoscopy / methods

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432779.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


67. Barbagallo GM, Caltabiano R, Parisi G, Albanese V, Lanzafame S: Giant cell ependymoma of the cervical spinal cord: case report and review of the literature. Eur Spine J; 2009 Jul;18 Suppl 2:186-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell ependymoma of the cervical spinal cord: case report and review of the literature.
  • Ependymomas account for 2-6% of all central nervous system neoplasms.
  • They develop from the ependymal cells that line the ventricular cavities of the brain and the central canal of the spinal cord, as well as from ependymal clusters in the filum terminale.
  • Giant cell ependymoma (GCE) is a rare subtype, with few cases reported, mostly in the brain.
  • We describe the case of a cervical spinal cord ependymoma with pleomorphic giant cells and focal calcifications occurring in a 25-year-old woman.
  • This case, the second giant-cell ependymoma to be described in the spinal cord and the first with focal calcifications, highlights the features of GCE and the discrepancy between the worrisome histological appearance, the surgical findings and the clinical relatively good prognosis.
  • [MeSH-major] Cervical Vertebrae. Ependymoma / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Neuropathol. 2001 Jan-Feb;20(1):31-7 [11220693.001]
  • [Cites] Pathol Int. 2003 Aug;53(8):539-46 [12895233.001]
  • [Cites] J Neurosurg. 2004 Jan;100(1 Suppl Spine):75-9 [14748579.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):880-3 [3286833.001]
  • [Cites] J Neurosurg. 1990 Mar;72(3):408-17 [2303876.001]
  • [Cites] Am J Surg Pathol. 1990 Aug;14(8):729-36 [2378394.001]
  • [Cites] Ultrastruct Pathol. 1994 Jan-Apr;18(1-2):43-6 [8191646.001]
  • [Cites] Am J Surg Pathol. 1996 Sep;20(9):1091-101 [8764746.001]
  • [Cites] Acta Neuropathol. 1997 Mar;93(3):310-6 [9083565.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):338-46 [9500776.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):398-403 [9578093.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):434-40 [9888153.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):721-31 [10201296.001]
  • [Cites] Pathol Res Pract. 2004;200(10):717-25 [15648610.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):367-8, 373 [16389948.001]
  • [Cites] J Neurosurg. 2006 Dec;105(6):908-11 [17405264.001]
  • [Cites] Clin Neurol Neurosurg. 2008 Feb;110(2):176-81 [18006220.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):77-85 [11763426.001]
  • (PMID = 18820954.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 20
  • [Other-IDs] NLM/ PMC2899556
  •  go-up   go-down


68. Azarpira N, Rakei M, Mokhtari M: Cytologic findings in malignant ependymoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):1023-6
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic findings in malignant ependymoma: a case report.
  • BACKGROUND: Intraoperative imprint cytology has proved to be a valuable tool in the diagnosis of central nervous system (CNS) tumors.
  • Ependymomas are uncommon glial neoplasms of the CNS, arising from ependymal lining of the ventricular system and central canal of the spinal cord.
  • Anaplastic ependymoma is a rare tumor that causes diagnostic difficulties in imprint cytology because of variable cytomorphologic findings.
  • Computed tomography of the head showed hydrocephalus with a large parietal lobe tumor with midline structural shift.
  • The tumor showed pseudorosettes with glial fibrillary acidic protein and epithelial membrane antigen expression.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Ependymoma / pathology
  • [MeSH-minor] Cell Aggregation. Fatal Outcome. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Rosette Formation. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053591.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


69. Benzagmout M, Boujraf S, Oulali N, Chbani L, Amarti A, Chakour K, Chaoui Mel F: Intradural extramedullary ependymoma: is there constantly a hormonal relationship? Surg Neurol; 2008 Nov;70(5):536-8; discussion 538
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intradural extramedullary ependymoma: is there constantly a hormonal relationship?
  • BACKGROUND: Ependymoma is a glial tumor that occurs in the central nervous system.
  • The authors report a case of spinal intradural extramedullary ependymoma in a male and discuss its pathogenesis as well as its clinical, radiological, and therapeutical features.
  • Magnetic resonance imaging revealed an enhanced cervical intradural extramedullary tumor extending from the bulbomedullary junction to the C3 level, with severe spinal cord compression.
  • Both surgical interventions demonstrated an intradural extramedullary ependymoma without attachment to the spinal cord or to the dura mater.
  • CONCLUSION: The insufficiency of hormonal theory to explain solely the pathogenesis of this tumor might reveal other potential factors that have not been discussed in earlier literature.
  • [MeSH-major] Ependymoma / diagnosis. Ependymoma / etiology. Gonadal Steroid Hormones / physiology. Neoplasm Recurrence, Local / etiology. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / etiology
  • [MeSH-minor] Adult. Cervical Vertebrae. Humans. Male. Sex Factors

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207493.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones
  •  go-up   go-down


70. Wang M, Tihan T, Rojiani AM, Bodhireddy SR, Prayson RA, Iacuone JJ, Alles AJ, Donahue DJ, Hessler RB, Kim JH, Haas M, Rosenblum MK, Burger PC: Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol; 2005 Oct;64(10):875-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma.
  • We present 8 examples of a neoplasm with features of both astrocytoma and ependymoma that may represent a distinct clinicopathologic entity.
  • Histologically, the variably infiltrative tumors were distinctively angiocentric with well-developed perivascular pseudorosettes in some cases.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / complications. Brain Neoplasms / pathology. Ependymoma / pathology. Epilepsy / etiology. Glioma / complications. Glioma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Microscopy, Electron. Mucin-1 / metabolism


71. Zhang S, Wang X, Zhang Z, Chen Y: Tanycytic ependymoma arising from the right lateral ventricle: a case report and review of the literature. Neuropathology; 2008 Aug;28(4):427-32
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tanycytic ependymoma arising from the right lateral ventricle: a case report and review of the literature.
  • Histologically, the tumor composed of nuclear dense zones consisting of a cluster of spindle cells and fibrillary zones consisting of streaming of cell processes.
  • The tumor cells showed the characteristics of monopolar or bipolar processes.
  • Some tumor cell processes extended to the vessel wall and formed ill-defined perivascular rosettes.
  • Four cases of tanycytic ependymoma arising from the lateral ventricle have been reported in literature.
  • Tanycytic ependymoma has slightly better prognosis than other ependymoma subtypes.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Lateral Ventricles / pathology
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312548.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


72. McGuire CS, Sainani KL, Fisher PG: Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg; 2009 Apr;110(4):725-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study.
  • OBJECT: Previous small studies disagree about which clinical risk factors influence ependymoma incidence.
  • The authors analyzed a large, population-based cancer registry to examine the relationship of incidence to patient age, sex, race, and tumor location, and to determine incidence trends over the past 3 decades.
  • For children, the age at diagnosis differed significantly by tumor location, with the mean age for patients with infratentorial tumors calculated as 5 +/- 0.4 years; for supratentorial tumors it was 7.77 +/- 0.6 years, and for spinal lesions it was 12.16 +/- 0.8 years. (Values are expressed as the mean +/- standard error [SE].
  • CONCLUSIONS: Males have a higher incidence of ependymoma than do females.
  • Ependymoma occurs within the CNS at distinct locations at different ages, consistent with hypotheses postulating distinct populations of radial glial stem cells within the CNS.
  • Ependymoma incidence appears to have increased over the past 3 decades, but only in adults.
  • [MeSH-major] Brain Neoplasms / epidemiology. Ependymoma / epidemiology. Spinal Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. SEER Program. Sex Factors. United States / epidemiology


73. Qian X, Goumnerova LC, De Girolami U, Cibas ES: Cerebrospinal fluid cytology in patients with ependymoma: a bi-institutional retrospective study. Cancer; 2008 Oct 25;114(5):307-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrospinal fluid cytology in patients with ependymoma: a bi-institutional retrospective study.
  • BACKGROUND: Ependymoma cells are known to occasionally exfoliate into cerebrospinal fluid (CSF).
  • However, the frequency of CSF involvement in patients with ependymoma is unclear, and to the authors' knowledge the cytomorphologic features of the tumor cells have not been described in detail to date.
  • In this study, the CSF findings in patients with ependymal neoplasms are summarized and the cytomorphologic features of ependymoma, including its variants, are illustrated.
  • METHODS: A search of the pathology databases of 2 medical centers was performed to identify all patients with a histologic diagnosis of ependymoma in whom CSF samples were examined.
  • RESULTS: In all, 177 patients with a diagnosis of ependymoma were identified.
  • The detection rate of tumor cells in CSF was 6.7% in 15 adults and 21.2% in 33 children, with an overall rate of 16.7%.
  • Of the 8 patients with positive and/or suspicious diagnoses, 5 ependymomas exhibited anaplastic features and 1 tumor was a myxopapillary ependymoma.
  • The positive samples were usually hypercellular, with cohesive epithelioid cells; long cytoplasmic processes resembling bipolar tanycytes were observed in the tanycytic variant of ependymoma.
  • [MeSH-major] Brain Neoplasms / cerebrospinal fluid. Brain Neoplasms / pathology. Ependymoma / cerebrospinal fluid. Ependymoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Retrospective Studies


74. Mansur DB, Perry A, Rajaram V, Michalski JM, Park TS, Leonard JR, Luchtman-Jones L, Rich KM, Grigsby PW, Lockett MA, Wahab SH, Simpson JR: Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):387-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative radiation therapy for grade II and III intracranial ependymoma.
  • PURPOSE: To retrospectively determine the long-term outcome of intracranial ependymoma patients treated with surgery and postoperative radiation therapy.
  • Forty patients had World Health Organization Grade II ependymoma, and 20 patients had Grade III ependymoma.
  • Supratentorial tumor location was independently associated with a worse disease-free survival.
  • No statistically significant effect on prognosis was observed with tumor grade, patient age, or radiation dose or volume.
  • CONCLUSION: Our long-term follow-up indicates that half of ependymoma patients will have disease recurrences, indicating the need for more effective treatments.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Ependymoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Female. Humans. Infant. Infratentorial Neoplasms / mortality. Infratentorial Neoplasms / radiotherapy. Infratentorial Neoplasms / surgery. Male. Middle Aged. Multivariate Analysis. Radiotherapy Dosage. Retrospective Studies. Supratentorial Neoplasms / mortality. Supratentorial Neoplasms / radiotherapy. Supratentorial Neoplasms / surgery. Survival Rate

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667957.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Takei H, Kosarac O, Powell SZ: Cytomorphologic features of myxopapillary ependymoma: a review of 13 cases. Acta Cytol; 2009 May-Jun;53(3):297-302
Genetic Alliance. consumer health - Myxopapillary ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphologic features of myxopapillary ependymoma: a review of 13 cases.
  • OBJECTIVE: To describe the cytologic features of myxopapillary ependymoma (MPE) on intraoperative smears, to analyze cytomorphologic parameters that may help in reaching the diagnosis and to discuss differential diagnosis.
  • STUDY DESIGN: Touch imprint smears of 13 MPE cases were reviewed and graded semiquantitatively for 14 cytomorphologic parameters; cellularity, myxoid background, isolated/dispersed tumor cells, "hyaline globules (HGs)," fibrillary cytoplasmic processes, papillary structures, perivascular pseudorosettes, epithelioid tumor cells (ETCs), intracytoplasmic mucin, intranuclear inclusions, nuclear grooves, mitosis, cytologic atypia and hemosiderin-laden macrophages.
  • RESULTS: Cytologic examination revealed variably cellular specimens composed of isolated and loosely aggregated tumor cells with round to oval or occasionally spindle-shaped nuclei; evenly distributed, finely granular chromatin; and fibrillary processes admixed with occasional ETCs.
  • CONCLUSION: Dual glial and epithelioid properties of tumor cells, well-known features of "regular" ependymomas, and a distinctive myxoid background with HGs strongly support a diagnosis of MPE and are of great help in excluding other mimics (e.g., other variants of ependymoma, metastatic mucinous adenocarcinoma, metastatic adenoid cystic carcinoma and chordoma).
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Ependymoma / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / secondary. Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / secondary. Cell Nucleus / pathology. Chordoma / diagnosis. Chordoma / secondary. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Mucins / metabolism. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19534270.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


76. Sakai Y, Matsuyama Y, Katayama Y, Imagama S, Ito Z, Wakao N, Kanemura T, Yoshida G, Sato K, Ando T, Nakamura H, Kato F, Yukawa Y, Ito K, Ishiguro N: Spinal myxopapillary ependymoma: neurological deterioration in patients treated with surgery. Spine (Phila Pa 1976); 2009 Jul 1;34(15):1619-24
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal myxopapillary ependymoma: neurological deterioration in patients treated with surgery.
  • OBJECTIVE.: To evaluate the postoperative outcomes of patients surgically treated for spinal myxopapillary ependymoma.
  • Neurologic deterioration after tumor resection is discussed in terms of the tumor encapsulation.
  • Most series published in the literature have covered postoperative tumor recurrence and role of adjuvant radiotherapy.
  • There were no tumor recurrence and progression of the remaining tumors.
  • CONCLUSION: In the unencapsulated ependymomas, tumor separation and manipulation of the surrounding neural tissue caused neurologic injury.
  • The heterogeneously enhanced ependymoma not only should be evaluated and treated meticulously, but also surgeons should not stick to total removal in infiltrated and adhering tumors as subtotally resected tumors with postoperative radiotherapy have not always recurred.
  • [MeSH-major] Ependymoma / surgery. Neurosurgical Procedures / adverse effects. Postoperative Complications / etiology. Spinal Cord / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease Progression. Female. Humans. Iatrogenic Disease / prevention & control. Magnetic Resonance Imaging. Male. Middle Aged. Polyradiculopathy / etiology. Polyradiculopathy / physiopathology. Polyradiculopathy / prevention & control. Spinal Cord Compression / etiology. Spinal Cord Compression / physiopathology. Spinal Cord Compression / prevention & control. Urinary Bladder, Neurogenic / etiology. Urinary Bladder, Neurogenic / physiopathology. Urinary Bladder, Neurogenic / prevention & control

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Myxopapillary ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564773.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Albayram S, Urger E, Oz B, Kafadar A, Islak C, Kocer N: MR Imaging of pial melanosis secondary to a posterior fossa melanotic ependymoma. AJNR Am J Neuroradiol; 2005 Apr;26(4):804-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR Imaging of pial melanosis secondary to a posterior fossa melanotic ependymoma.
  • MR imaging and histopathologic results revealed a posterior fossa melanotic ependymoma.
  • Histopathologic examination revealed that tumor cells and interstitial spaces had abundant melanin accumulation.
  • There was no evidence of hemosiderin in tumor cells and in interstitial spaces.
  • Pial melanin accumulation secondary to a posterior fossa melanotic ependymoma explained our MR findings.
  • [MeSH-major] Central Nervous System Diseases / diagnosis. Central Nervous System Diseases / etiology. Ependymoma / complications. Infratentorial Neoplasms / complications. Magnetic Resonance Imaging. Melanosis / diagnosis. Melanosis / etiology. Pia Mater
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814924.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Arsene D, Gherghiceanu M, Ardeleanu C, Danaila L: Highly cystic brain tumor: rare histological features in an ependymoma. Neuropathology; 2007 Aug;27(4):378-82
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly cystic brain tumor: rare histological features in an ependymoma.
  • Ependymoma is a slowly growing tumor appearing mostly in children and young adults.
  • [MeSH-major] Brain Neoplasms / ultrastructure. Cysts / ultrastructure. Ependymoma / ultrastructure
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Fourth Ventricle / ultrastructure. Humans. Immunohistochemistry. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899693.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


79. Zacharoulis S, Ashley S, Moreno L, Gentet JC, Massimino M, Frappaz D: Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. Childs Nerv Syst; 2010 Jul;26(7):905-11
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis.
  • INTRODUCTION: More than a third of children with ependymoma experience relapse, and despite multimodal treatment, less than 25% of them can then achieve long-term survival.
  • PATIENTS AND METHODS: We retrospectively analyzed 82 patients from four pediatric oncology European institutions in order to identify prognostic factors and influence of treatment modalities in relapsed ependymoma.
  • DISCUSSION: Relapsed ependymoma carries a very poor prognosis with an indolent chronic course, leading to death in approximately 90% of the patients.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Ependymoma / therapy
  • [MeSH-minor] Adolescent. Analysis of Variance. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Female. Humans. Infant. Male. Neoplasm Recurrence, Local. Neurosurgical Procedures. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2009 Oct;25(10):1293-301 [19360417.001]
  • [Cites] J Neurooncol. 1989 May;7(1):5-11 [2754456.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1288-96 [11230470.001]
  • [Cites] Pediatr Neurosurg. 1998 Apr;28(4):215-22 [9732252.001]
  • [Cites] Lancet Oncol. 2007 Aug;8(8):696-705 [17644039.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):563-70 [10550587.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3965-70 [18711186.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):169-73 [16200565.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31 [9589080.001]
  • [Cites] BMC Cancer. 2006 Sep 07;6:222 [16959039.001]
  • [Cites] J Neurooncol. 1999;45(1):61-7 [10728911.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):287-99 [16195801.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] J Chemother. 2008 Apr;20(2):263-8 [18467255.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):81-9 [17482475.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):34-40 [16874765.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):557-63 [2364367.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7621-31 [16234523.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):258-66 [19274783.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):87-97 [18406885.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):231-5 [17610266.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):135-43 [9524092.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):341-7 [9217048.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(10):1815-23 [19427780.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):856-60; discussion 860 [9092863.001]
  • (PMID = 20039045.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


80. Karabatsou K, Crooks D, Williams D, Buxton N: Combination of myxopapillary ependymoma and fatty filum in a child with tethered cord syndrome. Case report. J Neurosurg Pediatr; 2008 May;1(5):386-8
MedlinePlus Health Information. consumer health - Neural Tube Defects.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of myxopapillary ependymoma and fatty filum in a child with tethered cord syndrome. Case report.
  • The authors present a case of a child with a tethered spinal cord associated with a myxopapillary ependymoma.
  • Histological analysis of the fatty filum suggested the presence of a coexisting myxopapillary ependymoma.
  • The child made a good recovery with no evidence of tumor recurrence after 4-years of follow-up with serial MR imaging.
  • This unusual combination has not previously been reported in children, and to the authors' knowledge there is only one reported case in an adult.
  • [MeSH-major] Cauda Equina. Ependymoma / pathology. Lipoma / pathology. Neural Tube Defects / pathology. Peripheral Nervous System Neoplasms / pathology


81. Ma YT, Ramachandra P, Spooner D: Case report: primary subcutaneous sacrococcygeal ependymoma: a case report and review of the literature. Br J Radiol; 2006 May;79(941):445-7
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: primary subcutaneous sacrococcygeal ependymoma: a case report and review of the literature.
  • We report a 37-year-old woman with a subcutaneous sacrococcygeal ependymoma with iliac lymph nodal metastasis at presentation.
  • [MeSH-major] Ependymoma / diagnosis. Neoplasm Recurrence, Local / diagnosis. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers / analysis. Female. Glial Fibrillary Acidic Protein / analysis. Humans. Ilium. Immunohistochemistry / methods. Lymphatic Metastasis. Magnetic Resonance Imaging. Radiotherapy, Adjuvant. Reoperation. S100 Proteins / analysis. Sacrococcygeal Region. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16632628.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Glial Fibrillary Acidic Protein; 0 / S100 Proteins; 0 / Vimentin
  • [Number-of-references] 12
  •  go-up   go-down


82. Mogler C, Kohlhof P, Penzel R, Grenacher L, Haag GM, Schirmacher P, Mueller W: A primary malignant ependymoma of the abdominal cavity: a case report and review of the literature. Virchows Arch; 2009 Apr;454(4):475-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for malignant ependymoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A primary malignant ependymoma of the abdominal cavity: a case report and review of the literature.
  • Ependymomas generally arise in the central nervous system (CNS).
  • Here, we describe the first case of an overt malignant primary extraneural ependymoma in a young female patient.
  • Careful reevaluation together with extensive review of the literature and comparison of related cases established the diagnosis after treatment failure and tumor progression.
  • The tumor was large and firm with some small cysts and showed pseudorosettes with strong glial fibrillary acidic protein (GFAP) expression.
  • [MeSH-major] Abdominal Cavity / pathology. Diagnostic Errors. Ependymoma / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Autonomic Pathways / pathology. Combined Modality Therapy. Digestive System Surgical Procedures. Female. Gastrointestinal Neoplasms / pathology. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. Peripheral Nervous System Neoplasms / pathology

  • Genetic Alliance. consumer health - Ependymoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1979 Jul;44(1):326-33 [378364.001]
  • [Cites] Neurosurg Focus. 2003 Nov 15;15(5):E13 [15323470.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):3-32 [16512597.001]
  • [Cites] Neurol India. 1969 Apr-Jun;17(2):82-4 [5823288.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):421-3 [12946033.001]
  • [Cites] Am J Surg Pathol. 1993 Aug;17(8):764-78 [8393302.001]
  • [Cites] Am J Surg Pathol. 1982 Jun;6(4):283-92 [7114357.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):623-32 [8333561.001]
  • [Cites] Pathol Oncol Res. 1999;5(1):56-60 [10079380.001]
  • [Cites] J Neurosurg. 1979 Sep;51(3):383-91 [469584.001]
  • [Cites] Am J Surg Pathol. 2008 May;32(5):710-8 [18360284.001]
  • [Cites] J Neurooncol. 1992 Oct;14(2):135-42 [1432036.001]
  • [Cites] Medscape J Med. 2008 Feb 19;10 (2):41 [18382710.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):62-8 [3522133.001]
  • [Cites] Pathology. 2001 Feb;33(1):26-9 [11280604.001]
  • (PMID = 19238432.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glial Fibrillary Acidic Protein
  • [Number-of-references] 15
  •  go-up   go-down


83. Marinovic T, Grahovac G, Habek M, Lambasa S, Tomac D: Simultaneous conus medullaris ependymoma and cerebellar astrocytoma in the same patient. Clin Neuropathol; 2009 May-Jun;28(3):173-6
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous conus medullaris ependymoma and cerebellar astrocytoma in the same patient.
  • Multiple primary tumors in the central nervous system of different histological cell types are uncommon.
  • We report a patient who had pilocytic astrocytoma in the cerebellum and ependymoma in the cauda equina region, occurring simultaneously.
  • The suggested mechanism of this association is that primitive multipotent cells might have been displaced in the different CNS areas and developed in different tumor cells.
  • Multiplicity of primary CNS tumors should be considered in certain occasions, when clinical symptoms and signs are pointing in that direction.
  • [MeSH-major] Astrocytoma / pathology. Cerebellar Neoplasms / pathology. Ependymoma / pathology. Neoplasms, Multiple Primary / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Cauda Equina / pathology. Cauda Equina / surgery. Female. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537133.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Heuer GG, Stiefel MF, Bailey RL, Schuster JM: Acute paraparesis from hemorrhagic spinal ependymoma: diagnostic dilemma and surgical management. Report of two cases and review of the literature. J Neurosurg Spine; 2007 Dec;7(6):652-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute paraparesis from hemorrhagic spinal ependymoma: diagnostic dilemma and surgical management. Report of two cases and review of the literature.
  • Both patients underwent lumbar laminectomies for tumor resection.
  • The pathological finding in each case was myxopapillary ependymoma.
  • [MeSH-major] Ependymoma / blood supply. Ependymoma / complications. Hemorrhage / etiology. Neurosurgical Procedures. Paraparesis / diagnosis. Spinal Cord Neoplasms / blood supply. Spinal Cord Neoplasms / complications
  • [MeSH-minor] Acute Disease. Adult. Female. Follow-Up Studies. Humans. Lumbar Vertebrae. Magnetic Resonance Imaging. Male. Nervous System Diseases / etiology. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18074691.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


85. Gavin Quigley D, Farooqi N, Pigott TJ, Findlay GF, Pillay R, Buxton N, Jenkinson MD: Outcome predictors in the management of spinal cord ependymoma. Eur Spine J; 2007 Mar;16(3):399-404
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome predictors in the management of spinal cord ependymoma.
  • Twenty-six patients who underwent treatment of spinal cord ependymoma at a single institution were retrospectively analysed.
  • Extent of resection and the use of adjuvant radiotherapy did not influence PFS or OS; however, early diagnosis and treatment are paramount in the management of spinal ependymoma if a good functional outcome is to be achieved.
  • [MeSH-major] Ependymoma / radiotherapy. Ependymoma / surgery. Spinal Cord Neoplasms / radiotherapy. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Data Interpretation, Statistical. Disease-Free Survival. Humans. Middle Aged. Predictive Value of Tests. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spinal Cord. 1999 Nov;37(11):753-9 [10578245.001]
  • [Cites] J Neurosurg. 1954 Nov;11(6):616-21 [13222169.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):997-1002 [12209682.001]
  • [Cites] Neurosurgery. 2002 Nov;51(5):1162-72; discussion 1172-4 [12383361.001]
  • [Cites] Paraplegia. 1969 Nov;7(3):179-92 [5360915.001]
  • [Cites] Brain. 1972;95(1):109-22 [5023080.001]
  • [Cites] Cancer. 1975 Jun;35(6):1558-62 [1148990.001]
  • [Cites] Cancer. 1977 Aug;40(2):907-15 [890671.001]
  • [Cites] Radiology. 1980 May;135(2):473-9 [7367644.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):37-43 [7061255.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Jul;9(7):1093-6 [6863076.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):883-93 [4016681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1933-9 [2997089.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Mar;12(3):323-7 [3082807.001]
  • [Cites] Neurosurgery. 1989 Dec;25(6):855-9 [2601814.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):523-32 [2319309.001]
  • [Cites] J Neurosurg. 1993 Aug;79(2):204-9 [8331401.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):223-9 [8407395.001]
  • [Cites] Surg Neurol. 1996 Oct;46(4):322-8 [8876712.001]
  • [Cites] J Neurooncol. 2002 Apr;57(2):133-9 [12125974.001]
  • (PMID = 16865377.001).
  • [ISSN] 0940-6719
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2200709
  •  go-up   go-down


86. Preusser M, Wolfsberger S, Haberler C, Breitschopf H, Czech T, Slavc I, Harris AL, Acker T, Budka H, Hainfellner JA: Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathol; 2005 Feb;109(2):211-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival.
  • We investigated angiogenic patterns and expression of hypoxia-related tissue factors and their prognostic impact in 100 cases of intracranial ependymoma.
  • HIF-1alpha expression occurs in a significantly smaller fraction of cases and only in a few tumor cells without clear association with necrosis.
  • We conclude that bizarre vascular pattern, necrosis and high hypoxia score are frequently detectable in intracranial ependymoma, but seem less important for patient outcome than tumor cell proliferation.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Brain Neoplasms / metabolism. Carbonic Anhydrases / metabolism. Ependymoma / metabolism. Neovascularization, Pathologic. Transcription Factors / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic / physiology. Humans. Hypoxia-Inducible Factor 1, alpha Subunit. Immunohistochemistry / methods. In Situ Hybridization / methods. Infant. Male. Middle Aged. Regression Analysis. Retrospective Studies. Survival Analysis. Time Factors. Vascular Endothelial Growth Factor A / genetics. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15614581.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factor A; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


87. Lo SS, Abdulrahman R, Desrosiers PM, Fakiris AJ, Witt TC, Worth RM, Dittmer PH, Desrosiers CM, Frost S, Timmerman RD: The role of Gamma Knife Radiosurgery in the management of unresectable gross disease or gross residual disease after surgery in ependymoma. J Neurooncol; 2006 Aug;79(1):51-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of Gamma Knife Radiosurgery in the management of unresectable gross disease or gross residual disease after surgery in ependymoma.
  • PURPOSE/OBJECTIVE: To evaluate the efficacy and the toxicity of Gamma Knife (GK)-based stereotactic radiosurgery (SRS) in the management of gross disease in ependymoma.
  • CONCLUSIONS: GK-based SRS appears to be a feasible and safe treatment modality for patients with ependymoma with unresectable gross disease or gross residual disease after surgery.
  • SRS provides reasonable local control but out-of-field tumor progression remains an issue.
  • [MeSH-major] Brain Neoplasms / surgery. Ependymoma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual. Survival Analysis. Survival Rate. Treatment Outcome


88. Belcher R, Chahal HS, Evanson J, Afshar F, Marino S, Grossman AB: Recurrent pituitary ependymoma: a complex clinical problem. Pituitary; 2010 Jun;13(2):176-82
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pituitary ependymoma: a complex clinical problem.
  • We present a complex case of a recurrent ependymoma of the parasellar region which has been difficult to clinically manage due to its tendency to recurrence.
  • Our patient has had four operations over the last 28 years, with external beam radiotherapy, but still has residual tumor and is currently panhypopituitary and with significant visual loss.
  • Our case emphasises the recurrent nature of this rare but difficult tumor.
  • [MeSH-major] Ependymoma / diagnosis. Neoplasm Recurrence, Local / diagnosis. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18704689.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Saito R, Kumabe T, Kanamori M, Sonoda Y, Tominaga T: Dissemination limits the survival of patients with anaplastic ependymoma after extensive surgical resection, meticulous follow up, and intensive treatment for recurrence. Neurosurg Rev; 2010 Apr;33(2):185-91; discussion 191-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissemination limits the survival of patients with anaplastic ependymoma after extensive surgical resection, meticulous follow up, and intensive treatment for recurrence.
  • High resection rate, meticulous follow-up, and intensive treatment for recurrence improved the survival of patients with anaplastic ependymoma.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / pathology. Ependymoma / mortality. Ependymoma / pathology
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate


90. Pica A, Miller R, Villà S, Kadish SP, Anacak Y, Abusaris H, Ozyigit G, Baumert BG, Zaucha R, Haller G, Weber DC: The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1114-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network.
  • PURPOSE: The aim of this study was to assess the outcome of patients with primary spinal myxopapillary ependymoma (MPE).
  • Fifteen patients presented treatment failure at the primary site only, whereas 2 and 1 patients presented with brain and distant spinal failure only.
  • Three and 2 patients with local failure presented with concomitant spinal distant seeding and brain failure, respectively.
  • One patient failed simultaneously in the brain and spine.
  • Age greater than 36 years (p = 0.01), absence of neurologic symptoms at diagnosis (p = 0.01), tumor size >or=25 mm (p = 0.04), and postoperative high-dose RT (p = 0.05) were variables predictive of improved PFS on univariate analysis.
  • CONCLUSIONS: The observed pattern of failure was mainly local, but one fifth of the patients presented with a concomitant spinal or brain component.
  • Postoperative high-dose RT appears to significantly reduce the rate of tumor progression.
  • [MeSH-major] Ependymoma / radiotherapy. Ependymoma / surgery. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Brain Neoplasms / secondary. Child. Combined Modality Therapy / methods. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Treatment Failure. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Myxopapillary ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19250760.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


91. Wu WX, Yu SZ, Sun CY, Wang Q, Jin SM, An TL: [Detection of chromosomal imbalance in ependymoma by comparative genomic hybridization]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):148-52
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of chromosomal imbalance in ependymoma by comparative genomic hybridization].
  • OBJECTIVE: To investigate genomic DNA imbalances in ependymomas (EDMs) and their correlations with the tumor histological types, grades, locations, patients' gender and age.
  • CONCLUSIONS: The frequencies of chromosomal imbalances in EDMs decrease as the tumor grade increases.
  • Characteristic chromosomal imbalances in each subtype may play an important role in determination of histological phenotypes and tumor grades.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Aberrations. Ependymoma / genetics. Spinal Cord Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Comparative Genomic Hybridization. DNA, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575847.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


92. Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA: Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol; 2009 Mar;10(3):258-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study.
  • BACKGROUND: Therapy for ependymoma includes aggressive surgical intervention and radiotherapy administered by use of methods that keep the risk of side-effects to a minimum.
  • METHODS: Between July 11, 1997, and Nov 18, 2007, 153 paediatric patients (median age 2.9 years [range 0.9-22.9 months]) with localised ependymoma were treated.
  • 85 patients had anaplastic ependymoma; the tumours of 122 were located in the infratentorial region, and 35 had received previous chemotherapy.
  • The incidence of secondary malignant brain tumour at 7 years was 2.3% (0-5.6) and brainstem necrosis 1.6% (0-4.0).
  • Overall survival was affected by tumour grade (anaplastic vs differentiated: HR 3.98 [95% CI 1.51-10.48]; p=0.0052), extent of resection (gross total vs near total or subtotal: 0.16 [0.07-0.37]; p<0.0001), and ethnic origin (non-white vs white: 3.0 [1.21-7.44]; p=0.018).
  • EFS was affected by tumour grade (anaplastic vs differentiated: 2.52 [1.2705.01]; p=0.008), extent of resection (gross total vs near total or subtotal: 0.20 [0.11-0.39]; p<0.0001]), and sex (male vs female: 2.19 [1.03-4.66]; p=0.042).
  • Distant recurrence was only affected by tumour grade (anaplastic vs differentiated: 4.1 [1.2-14.0]; p=0.017).
  • INTERPRETATION: Treatment of ependymoma should include surgery with the aim of gross-total resection and conformal, high-dose, postoperative irradiation.
  • [MeSH-major] Brain Neoplasms / therapy. Ependymoma / therapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Prospective Studies. Treatment Failure

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 2000;39(1):97-100 [10752661.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1288-96 [11230470.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):87-94 [11949831.001]
  • [Cites] J Neurosurg. 2002 Oct;97(4):827-35 [12405370.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1336-45 [15050308.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):255-61 [15332330.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Br J Cancer. 1976 Dec;34(6):585-612 [795448.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Neurosurgery. 1995 Oct;37(4):655-66; discussion 666-7 [8559293.001]
  • [Cites] Med Pediatr Oncol. 1996 Jul;27(1):8-14 [8614396.001]
  • [Cites] Med Pediatr Oncol. 1997 Aug;29(2):79-85 [9180907.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):695-703 [9525716.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31 [9589080.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):387-91 [15667957.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1546-54 [16115736.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5283-90 [17114662.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):34-40 [16874765.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):432-41 [17559078.001]
  • [Cites] Lancet Oncol. 2007 Aug;8(8):696-705 [17644039.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):87-97 [18406885.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):987-93 [18258381.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):979-86 [18325681.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3965-70 [18711186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):892-9 [18395355.001]
  • [CommentIn] Lancet Oncol. 2009 Mar;10(3):206-7 [19261252.001]
  • (PMID = 19274783.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS429992; NLM/ PMC3615425
  •  go-up   go-down


93. Akyurek S, Chang EL, Yu TK, Little D, Allen PK, McCutcheon I, Mahajan A, Maor MH, Woo SY: Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center. J Neurooncol; 2006 Nov;80(2):177-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center.
  • This study was undertaken to determine the disease outcomes in patients treated with surgery alone or surgery and adjuvant radiotherapy (RT) for myxopapillary ependymoma (MPE) of the spine.
  • Regardless of the extent of resection, adjuvant RT appears to significantly reduce the rate of tumor progression.
  • [MeSH-major] Ependymoma / drug therapy. Ependymoma / radiotherapy. Spinal Cord Neoplasms / drug therapy. Spinal Cord Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neurologic Examination. Prognosis. Retrospective Studies. Salvage Therapy. Survival Analysis. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Myxopapillary ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2007 May;82(3):323-5 [17206476.001]
  • (PMID = 16648988.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


94. Eroes CA, Zausinger S, Kreth FW, Goldbrunner R, Tonn JC: Intramedullary low grade astrocytoma and ependymoma. Surgical results and predicting factors for clinical outcome. Acta Neurochir (Wien); 2010 Apr;152(4):611-8
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramedullary low grade astrocytoma and ependymoma. Surgical results and predicting factors for clinical outcome.
  • MATERIAL AND METHODS: All consecutive adult patients with intramedullary astrocytomas or ependymomas (except filum terminale ependymomas) were included.
  • Complete tumor resection was achieved in 79% of ependymomas, 50% of astrocytomas WHO grade I, and 14% of astrocytomas WHO grade II (significantly more often in ependymomas than in astrocytomas, p < 0.05).
  • Preoperative MCS <3 and extent of tumor <5 levels were significantly (p = 0.01 and p < 0.05) associated with a favorable outcome (MCS <3) in early and late follow-up.
  • CONCLUSION: An MCS of less than 3 and a tumor extent of less than 5 levels are the most important factors for a favorable postoperative functional outcome.
  • Therefore, surgery should be initiated before significant clinical symptomatology or substantial tumor growth occurs.
  • [MeSH-major] Astrocytoma / surgery. Ependymoma / surgery. Spinal Cord Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20119838.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


95. Yi W, Haapasalo H, Holmlund C, Järvelä S, Raheem O, Bergenheim AT, Hedman H, Henriksson R: Expression of leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins in human ependymoma relates to tumor location, WHO grade, and patient age. Clin Neuropathol; 2009 Jan-Feb;28(1):21-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins in human ependymoma relates to tumor location, WHO grade, and patient age.
  • LRIG1 has been shown to be a suppressor of tumor growth by counteracting the signaling of epidermal growth factor receptor (EGFR) family members, including EGFR (ERBB1).
  • The indications that expression and subcellular localization of LRIG proteins could be pathogenetically associated with specific clinicopathological features of ependymoma tumors might be of importance in the carcinogeneses and tumor progression of human ependymomas.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Membrane Proteins / biosynthesis. Spinal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Cell Nucleus / metabolism. Child. Child, Preschool. Cytoplasm / metabolism. Female. Gene Expression. Humans. Immunohistochemistry. Infant. Male. Membrane Glycoproteins / biosynthesis. Middle Aged. Tissue Array Analysis. World Health Organization


96. Takano T, Akahira J, Moriya T, Murakami T, Tanaka M, Goto M, Niikura H, Ito K, Mikami Y, Okamura K, Yaegashi N: Primary ependymoma of the ovary: a case report and literature review. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1138-41
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ependymoma of the ovary: a case report and literature review.
  • Ependymoma is a glioma with differentiation toward ependymal cells that usually arises in the central nervous system.
  • Ovarian ependymoma is extremely rare, and the treatment strategies for this disease have not been established.
  • This is the first report of a patient with advanced ovarian ependymoma who received fertility-sparing surgery and is now alive without disease.
  • Microscopic examination revealed a highly cellular tumor composed of small cells with hyperchromatic, round-to-oval nuclei and scanty cytoplasm.
  • After thorough pathologic examination, she was diagnosed as having stage IIIC ovarian ependymoma.
  • Although rare, primary ovarian ependymoma must be kept in mind in the differential diagnosis of ovarian tumors, especially in young women.
  • Administration of etoposide-based chemotherapy along with cytoreductive surgery is a potential standard treatment for advanced ovarian ependymoma.
  • [MeSH-major] Ependymoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Gynecologic Surgical Procedures. Humans. Reoperation

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343197.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 16
  •  go-up   go-down


97. Ishizawa K, Komori T, Hirose T: Stromal cells in hemangioblastoma: neuroectodermal differentiation and morphological similarities to ependymoma. Pathol Int; 2005 Jul;55(7):377-85
Genetic Alliance. consumer health - Hemangioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal cells in hemangioblastoma: neuroectodermal differentiation and morphological similarities to ependymoma.
  • In three cases, another component, known as a cellular variant, where epithelioid tumor cells were arranged in nests encircled by capillaries and/or in pseudorosette-like structures, was noted.
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / analysis. Antigens, CD56 / analysis. Antigens, CD57 / analysis. Cell Adhesion Molecules / analysis. Cell Differentiation. Child. Cytoskeletal Proteins. Diagnosis, Differential. Ependymoma / pathology. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron. Middle Aged. Neuroectodermal Tumors / pathology. Phosphoproteins / analysis. Phosphopyruvate Hydratase / analysis. S100 Proteins / analysis. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor Receptor-2 / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982211.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / Antigens, CD57; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Cytoskeletal Proteins; 0 / Phosphoproteins; 0 / S100 Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / Vimentin; 0 / ezrin; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


98. Benesch M, Spiegl K, Winter A, Passini A, Lackner H, Moser A, Sovinz P, Schwinger W, Urban C: A scoring system to quantify late effects in children after treatment for medulloblastoma/ependymoma and its correlation with quality of life and neurocognitive functioning. Childs Nerv Syst; 2009 Feb;25(2):173-81
MedlinePlus Health Information. consumer health - Neurologic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A scoring system to quantify late effects in children after treatment for medulloblastoma/ependymoma and its correlation with quality of life and neurocognitive functioning.
  • BACKGROUND: The aim of this study was to quantify the severity of late effects by a simple numerical score (late effects severity score, LESS) in patients who received radiochemotherapy for medulloblastoma or ependymoma.
  • Twenty-three patients with medulloblastoma (n = 18) or ependymoma (n = 5) underwent extensive neurocognitive and QoL testing at a median of 56 months (range, 1-174) after the end of treatment.
  • Eight patients with low-grade glioma (LGG) who underwent tumor resection only served as control group.
  • RESULTS: Patients with medulloblastoma/ependymoma had significantly higher LESS and significantly lower Wechsler Adult Intelligence Scale (WAIS)/Wechsler Intelligence Scales for Children (WISC) scores compared to patients with LGG.
  • Comparison of QoL and late effects in patients with medulloblastoma/ependymoma demonstrated a significant negative correlation only for neurological late effects and the KINDL score suggesting that younger patients with more severe late effects reported on a worse QoL.
  • CONCLUSIONS: This LESS seems to be a simple and practical tool to quantify late effects in former brain tumor patients.
  • [MeSH-major] Ependymoma / therapy. Medulloblastoma / therapy. Nervous System Diseases / physiopathology. Quality of Life
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cognition / drug effects. Cognition / physiology. Cognition / radiation effects. Combined Modality Therapy / adverse effects. Drug-Related Side Effects and Adverse Reactions. Endocrine System / drug effects. Endocrine System / physiopathology. Endocrine System / radiation effects. Female. Follow-Up Studies. Hearing / drug effects. Hearing / physiology. Hearing / radiation effects. Humans. Infant. Magnetic Resonance Imaging / methods. Male. Outcome Assessment (Health Care) / methods. Radiotherapy / adverse effects. Time Factors. Verbal Learning / drug effects. Verbal Learning / physiology. Verbal Learning / radiation effects. Vision, Ocular / drug effects. Vision, Ocular / physiology. Vision, Ocular / radiation effects. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • [Cites] Neuropediatrics. 2005 Dec;36(6):357-65 [16429375.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] Qual Life Res. 1998 Jul;7(5):399-407 [9691720.001]
  • [Cites] Schweiz Arch Neurol Psychiatr (1985). 1990;141(1):21-30 [1690447.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3476-86 [10550145.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2064-80 [16919771.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):135-8 [6722738.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):399-408 [15231246.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):592-9 [2066756.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2527-35 [16735705.001]
  • [Cites] Cancer. 1982 Apr 15;49(8):1580-6 [7066864.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3720-8 [10577843.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):137-45 [10477017.001]
  • [Cites] J Pediatr. 1978 Dec;93(6):903-9 [214533.001]
  • [Cites] Childs Nerv Syst. 1990 Mar;6(2):60-5 [2340529.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1723-8 [9586884.001]
  • [Cites] Eur J Pediatr. 2000 Oct;159(10):750-8 [11039130.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):695-703 [9525716.001]
  • [Cites] J Neurooncol. 2005 May;72(3):245-53 [15937648.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5493-500 [16110009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):269-79 [10661332.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):381-6 [8276653.001]
  • [Cites] Int J Cancer Suppl. 1999;12:83-6 [10679876.001]
  • [Cites] J Pediatr. 2002 Nov;141(5):683-8 [12410198.001]
  • [Cites] Pediatr Neurol. 2003 Jan;28(1):42-7 [12657419.001]
  • [Cites] J Neurosurg. 1994 Jun;80(6):1004-10 [8189255.001]
  • [Cites] Arch Surg. 2007 Nov;142(11):1043-8 [18025331.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):341-7 [9217048.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):199-205 [16739030.001]
  • (PMID = 18974990.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


99. Lensgraf AG, Young KJ: Ependymoma of the spinal cord presenting in a chiropractic practice: 2 case studies. J Manipulative Physiol Ther; 2006 Oct;29(8):676-81
MedlinePlus Health Information. consumer health - Chiropractic.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymoma of the spinal cord presenting in a chiropractic practice: 2 case studies.
  • An overview of treatment and outcome for an ependymoma at T12-L1 and L1-L2 is discussed.
  • Follow-up telephone interviews (3, 6, 12, 24, and 40 months) revealed the patient doing well.
  • The second case did not require radiation therapy and was doing well at 4, 10, 12, and 18 months; the patient returned for unrelated treatment 1 year after the surgery.
  • [MeSH-major] Back Pain / etiology. Chiropractic. Ependymoma / complications. Ependymoma / surgery. Referral and Consultation. Spinal Cord Neoplasms / complications
  • [MeSH-minor] Adult. Female. Humans. Intestines / physiopathology. Magnetic Resonance Imaging. Male. Manipulation, Chiropractic. Middle Aged. Motor Neuron Disease / etiology. Motor Neuron Disease / physiopathology. Neurosurgical Procedures. Radiotherapy, Adjuvant. Urinary Bladder / physiopathology

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Back Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17045102.001).
  • [ISSN] 1532-6586
  • [Journal-full-title] Journal of manipulative and physiological therapeutics
  • [ISO-abbreviation] J Manipulative Physiol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Palacio FJ, Fornet I, Morillas P, López MA, Reina MA, López A: [Continuous subarachnoid analgesia and anesthesia for labor and cesarean section in a patient who had previously undergone surgery for ependymoma]. Rev Esp Anestesiol Reanim; 2008 Jun-Jul;55(6):371-4
MedlinePlus Health Information. consumer health - Cesarean Section.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Continuous subarachnoid analgesia and anesthesia for labor and cesarean section in a patient who had previously undergone surgery for ependymoma].
  • We report the case of a 38-year-old primipara who had undergone surgery 2 years earlier for an intradural ependymoma at L2-L3 and who was currently asymptomatic.
  • [MeSH-minor] Adult. Ependymoma / surgery. Female. Humans. Pregnancy. Spinal Cord Neoplasms / surgery

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18693664.001).
  • [ISSN] 0034-9356
  • [Journal-full-title] Revista española de anestesiología y reanimación
  • [ISO-abbreviation] Rev Esp Anestesiol Reanim
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down






Advertisement